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ABSTRACT OF THE DISSERTATION

Resveratrol Regulates IGF-II and Cathepsin D in Breast Cancer Cells
by

Sharda Kalla Vyas

Doctor ofPhilosophy, Graduate Program in Anatomy
Loma Linda University, Loma Linda California, June 2005
Daisy D. De Leon, Chairperson

Breast cancer is the most common type of cancer among women in the US.

Phytoestrogen resveratrol(RSV)has been described as a potential ehemotherapeutic

agent, but has been associated with breast cancer cell growth and cell death. RSV binds
to estrogen receptors(ER)and functions as a mixed estrogen agonist/antagonist. The
mechanism by which RSV regulates breast cancer growth is largely unknown, but it
likely targets factors regulated by estrogens. Insulin-like growth factor II(IGF-II) and its
precursor (proIGF-II) are estrogen-regulated mitogens that are over-expressed in breast
carcinoma. Thus, I hypothesized that IGF-II/proIGF-II might mediate the biphasic
effects ofRSV on breast cancer cell growth.

The hypothesis was tested by the following specific aims:(I)Determine RSV

modulation of breast cancer cell growth in ER +/- cells; (2)Identify the effect ofRSV on
IGF-II/proIGF-II expression in breast cancer cells;(3)Determine whether IGF-

II/proIGF-II mediates RSV effects on breast cancer cells;(4)Identify IGF-II/proIGF-II

targets involved in breast cancer cell modulation - i.e. apoptotie genes and Cathepsin D
(CD), an estrogen-regulated protein elevated in breast cancer.

RSV displays a biphasic effect on cell growth and IGF-II expression in ER+ breast

carcinoma cells. In ER+ cells(MCF-7, T47D),RSV at lO'^M induces a 2-fold increase

Xll

in cell growth with an increase in proIGF-II expression (2.5 fold by Northern) and

seeretion(2 fold by Western)24 hr post-treatment. While RSV at lO'^^M inhibited cell
growth, deereased proIGF-II expression, and redueed proIGF-II secretion(by 50%,50%
and 30%,respectively). Furthermore, bloeking antibody to the IGF-I receptor(mediator
ofIGF-II signal transduetion) completely inhibited the growth stimulatory effeet ofRSV

10'^ M. In contrast, ER- cells(MCF-lOA,Hs578t)showed no RSV-related inerease in
growth or changes in IGF-II/proIGF-II expression.

Over-expression ofIGF-II, either endogenous or exogenous via an expression
plasmid, induced an increase in CD secretion(2 fold)irrespective ofER status. In

addition, the RSV (10"^M)-induced down-regulation ofIGF-II led to a decrease in the
anti-apoptotic proteins Bcl-2 and survivin (2.5 and 2 fold respeetively) that could be
reversed by exogenous proIGF-II(lOOng/ml) or by over-expression of a proIGF-II
expression plasmid.

In summary,these data demonstrate that RSV could increase the risk of breast cancer

growth at low coneentration by increasing proIGF-II levels. Furthermore,these data
suggest that IGF-II/proIGF-II manifests its effeets on breast cancer growth by inducing
CD secretion and up-regulating the anti-apoptotie proteins Bel-2 and survivin.

Xlll

CHAPTER ONE
INTRODUCTION

Breast cancer results after normal mammary epithelial cells sustain genetic

damage to acquire the phenolypes characteristic of malignancy: unregulated
proliferation, protection from cell death, and ability to metastasize. In addition to
estrogen, breast cancer cells respond to various stimuli including growth factors.
Since breast cancer metastasis is directly associated with death rate, identifying and

understanding the growth regulatory pathways involved in breast cancer progression
is essential to identify new therapeutic targets.

Recently, resveratrol(RSV,3,5,4'-trihydroxy-tra«5-stilbene) has been described
as a potential chemotherapeutic agent for breast cancer. RSV is a naturally occurring

phytochemical that can be found in approximately 72 plant species, and is presently
considered a potential chemopreventive treatment for breast cancer. RSV can act as both

a mixed agonist/antagonist for ERs a and P, although the mechanism of action for this

phytoestrogen and its target genes are mostly unknown. Whereas some investigators have
demonstrated antiproliferative effects in the MDA-MB-231,KPC-I, MKL-F,T47D and
MCF-7 cell lines(Clemment et al. 1998, Mgbonyebi et al 1998, Nakagawa et al. 2001),
others have demonstrated growth enhancement in T47D and MCF-7 cells(Gehm et al.

1997, Basly et al. 2000). The latter effect appears to be due to the potential estrogenic
effects of RSV. However,the precise mechanisms by which RSV exerts these biphasic
effects are not well known, but likely involve the modulation ofspecific estrogenregulated targets.

The insulin-like growth factor-II (IGF-II)is a potent estrogen-regulated mitogen
that stimulates cell proliferation and inhibits apoptosis of breast cancer cells. IGF-II gene
14

expression is paternally imprinted and regulated by tumor suppressor genes such as p53,
WTl (Wilms' tumor gene), GC factor(GCF)(Zhang et al. 1996, Toretsky and Helman
196, Kitadai et al. 1993)and as mentioned by 17-Estradiol(E2)(Yee and Lee, 2000).
Furthermore, the complex regulation ofIGF-II expression involves both,

developmentally regulated promoters(P1-P4) and alternative splicing of different
untranslated leader sequences(Werner et al. 1994). IGF-II is translated as a prohormone
that is cleaved and glycosylated to produce isoforms ranging from 21 (proIGF-II)to 7.5

kDa(mature IGF-II)(Gowan et al. 1987). ProIGF-II is the predominant form secreted by
most tumors and it is biologically active(Gowan et al. 1987, Hoppener et al. 1988, Reeve
et al. 1995, Hasselbacher et al. 1987). While IGF-II overexpression does not cause

malignant tumor growth in some organs, such as the uterus(Ward et al. 1994),in the
mammary gland excess IGF-II contributes to tumor formation. This provides evidence for
the role ofIGF-II signaling in malignant transformation. IGF-II also plays a role in the
maintenance ofthe malignant phenotype. It has also been shown that malignant breast

epithelial cells can induce expression ofIGF-II in the stroma in vitro. IGF-II binds
several receptors including the IGF-II/Mannose 6-phosphate receptor(IGF-II/M6PR),
IGF-I receptor(IGF-IR) and the insulin receptor isoform A (IR-A). IGF-II mitogenic
effects are mediated through the IGF-IR and the IR-A while insulin binding to IR-A

stimulates metabolic pathways (Sciacca et al 1999, Sciacca et al. 2002, Denley et al.

2004). IGF-II binding to the IGF-II/M-6-P receptor results in intracellular degradation of
IGF-II and decreased signaling through the IGF-I and IR-A receptors(Scott and Firth
2004). The IGF-II/M6PR binds both IGF-II and other mannose 6 phosphate substrates

such as Cathepsin D, which have separate binding sites. Our laboratory has previously
shown that expression of pro-IGF-II leads to an increase in Cathepsin D secretion in
15

MCF-7 breast cancer cells(DeLeon et al. 1996).

Cathepsin D(CD)is an aspartyl protease regulated by estrogen and overexpressed
in a variety of human cancers including estrogen receptor(ER)negative breast
carcinomas (Rochefort et al, 1989). Cathepsin D is synthesized as preprocathepsin D

(pCD). The single chain procathepsin D(52 kDa)is autoactivated to CD(51 kDa)and
further processed and glycosylated into several distinct forms(51-14 kDa), which are
enzymatically active forms(Westley et al. 1996,Iwase et al. 1997). In estrogen receptor

(ER)positive breast cancer cells, overexpression of procathepsin D has been correlated
with lymphatic metastasis, relapse and short disease survival in several retrospective
clinical studies (Brouillet et al. 1997, Rochefort et al. 1996). The CD gene has a mixed
structure with the general features of housekeeping genes (constitutively secreted, high
G+C content and potential Spl binding sites) and those of a regulated facultative gene

that includes a TATAA sequence. In ER positive breast cancer eell lines, CD is regulated
by npestradiol (E2). Transcription from the CD gene can be initiated at five sites

spanning 52 bp; of the five start sites, estrogen stimulates transcription only from the site
located downstream ofthe TATA box at -20; in contrast, low proportions of TATA-

dependent transcription were observed in estrogen-unresponsive breast cancer cell lines,
suggesting that factors other than estrogens may also stimulate TATA-dependent

transcription. In TATA-independent transcription, like observed in ER(-) cell lines, the
proportion oflonger CD mRNA is increased. This effect might have biological
consequences in terms of stability or initiation oftranslation and subcellular localization

of the protein (Cavailles et al, 1993). ER targeting of upstream stimulatory factor 1 and 2(USF-1, USF-2)is a critical step in hormone activation of CD transcription in human
breast cancer cells. In contrast, CD is secreted constitutively in ER(a)negative cell lines.
16

The mechanism by which IGF-II inhibits apoptosis is not well known. Apoptosis
is an essential physiological process for the selective elimination of cells; moreover

impaired apoptosis is a crucial step in tumorigenesis that endows neoplastie cells with
multiple advantages. So, neoplastie progression reflects loss of normal apoptotic
mechanisms. The Bcl-2 family, which consists of anti- and pro-apoptotic members, is the
best characterized family involved in the regulation of apoptotic cell death. The anti-

apoptotic member Bcl-2(B cell lymphoma 2)localizes in the mitochondrial membrane as
well as in the endoplasmic retieulum membrane and nuclear envelope. Bcl-2 prevents

apoptosis either by sequestering caspases preforms or by preventing the release of
mitochondrial apoptogenic factors such as cytochrome e and AIF (apoptosis-inducing

factor) into the cytoplasm (15-17). In MCF-7 cells Bcl-2 levels can be modulated by
estradiol(E2)(18,19). These data suggest a potential link between estrogen, Bcl-2, and
estrogen mediated IGF-II in the inhibition of apoptosis in breast cancer cells.
Another potentially relevant inhibitor of apoptosis is Survivin, a member ofthe
inhibitor of apoptosis proteins family(lAPs) whose overexpression has been consistently
associated with inhibition of cell death initiated by both the extrinsic and intrinsic

apoptotic pathways(20, 21). Survivin is strongly and diffusely expressed in embryonic
and fetal organs, and overexpressed in a variety oftumors including breast carcinomas.
Survivin is known to bind directly to and inhibit caspase -3 and -7(20), and its mRNA

and protein levels can be downregulated by the tumor suppressor p53(which is also
linked to IGF-II regulation).

In recent years, RSV has gained considerable attention due to its potential as a

ehemotherapeutic agent for breast carcinomas. Although several reports have shown that
RSV displays a biphasic effect on breast cancer cell growth, proteins involved in the
17

biphasic response and risks associated with RSV usage remain mostly unknown. The
studies conducted in this dissertation demonstrate that RSV could increase the risk of

breast cancer growth at low concentration by increasing proIGF-II levels. ProIGF-II not

only exerts its mitogenic effect in an autocrine/paracrine manner, but also by inducing
CD secretion and up-regulating the anti-apoptotic proteins Bcl-2 and survivin.

The study described in this dissertation evaluates the following specific aims:(1)
Determine RSV modulation of breast cancer cell growth in estrogen receptor positive and

negative cells.(2)Identify the effect ofRSV on IGF-II expression in breast cancer cells;
(3)Determine whether IGF-II mediates RSV effects on breast cancer cells;(4)Identify
IGF-II regulated targets involved in breast cancer cell modulation- i.e. genes involved in
the apoptotic pathway and Cathepsin D(CD), an estrogen regulated protein associated
with breast cancer cell growth and released under the influence ofIGF-II.

18

CHAPTER TWO

REVIEW OF THE LITERATURE
Resveratrol

Structure and Function

Resveratrol(RSV)3,5,4' trihydroxystilbene, is one of a group ofcompounds that
are produced by plants in times of environmental stress (Derks and Creasy, 1989). RSV
has been found in at least 72 plant species, a number of which are components of the

human diet, such as grapes, peanuts and mulberries(Derks and Creasy 1989). Grape skin
contains about 50-100 pg/gr ofRSV (Jeandet et al. 1991). RSV synthesis ffomp-

coumaryl CoA and malonyl CoA is induced by stress, injury, infection or UV-irradiation.
RSV exhibits structural similarity with the synthetic estrogen diethylstilbestrol

(DES), and like stilbenes or triphenylethylenes, it exists as geometric isomers [the (E)- or
trans-isomer and the (Z)- or cis isomer]. These two isoforms may differ in their

scavenging, estrogenic or anti-estrogenic activities; moreover, these two geometrical
isomers are present in the human diet(Basly et al. 2000).

RSV exact physiological function is not known, but in plants it may have roles

protecting them against fungal infections and in conferring disease resistance. One of its
richest sources is the herb Polygonum cuspidatum, which has been used in Asian folk

medicine (Soleas et al. 1997). RSV exerts antioxidant and anti-inflammatory activities,
induces phase 11 drug-metabolizing enzymes(CYPlAl,CYP2A6,and CYP3A4),and it
is able to inhibit cyclooxygenase activity and transcription; thus it has multiple effects on
cellular events associated with carcinogenesis (Jang et al. 1997). It may also have in vivo

activities in modulating indices of platelet aggregation and lipid metabolism, which could
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explain the epidemiological evidence that RSV decreases coronary heart disease
mortality (Soleas et al. 1997). RSV has also been shovm to have growth inhibitory effect
in several human cancer cell lines and in animal models for carcinogenesis (Jang et al.

1997, Carbo et al. 1999, Tessitore et al. 2000). In HL60 promyelocytic leukemia cells,

treatment with RSV led to growth inhibition, induction of apoptosis, S-G2 phase cell

arrest, and myelomonocytic differentiation (Clemment et al. 1998, Ragione et al. 1998).
RSV also displayed antiproliferative effect in JB6 mouse epidermal, CaCo-2 colorectal
and A431 epidermoid carcinoma cell lines(Huang et al. 1999, Schneider et al. 2000,
Ahmad et al. 2001). RSV effects in breast cancer cells lines are more complicated.
Whereas some investigators have demonstrated antiproliferative effects in the MDA-MB231, KPC-l, MKL-F,T47D and MCF-7 cell lines(Clemment et al. 1998, Mgbonyebi et

al. 1998, Nakagawa et al. 2001), others have demonstrated growth enhancement in T47D
and MCF-7 cells(Gehm et al. 1997, Basly et al. 2000). The latter effect appears to be due

to the potential estrogenic effects of RSV. However,the precise mechanisms by which
RSV exerts these antitumor effects are not well known. Limited epidemiological and

clinical evidence suggest that RSV is well tolerated during human consumption and that
it may offer benefits with respect to atherosclerotic heart disease (Goldberg et al. 1996,
Pace-Asiak et al. 1996). Although RSV is available commercially as a dietary

supplement, there are no published controlled clinical studies demonstrating either its
efficacy or safety in the treatment or prevention of cancer or coronary artery disease.

RSV-Estrogen Receptor(ER)Interactions

RSV has been categorized as a phytoestrogen based on its ability to bind and
activate the ERa(Gehm et al. 1997). More recent data have shown that RSV also binds
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to a second subtype of ER,the ERP(Bowers et al. 2000, Bhat and Pezzuto 2001).
However,in contrast to other phjdoestrogens, e.g., genestein and coumestrol, which bind
with greater affinity to ERP than ERa(An et al. 2001, Kuiper 1998), RSV binds both ER
subtypes with similar affinity(Bowers et al. 2000)or with only a small preference to

ERp (Bhat and Pezzuto 2001). The effect(s) of RSV on breast cancer cell growth and ERmediated activation of gene transcription remain controversial; Gehm (1997)found that

RSV stimulated growth ofthe estrogen-dependent breast cancer cell line T47D,and that
the stimulation was blocked by the estrogen antagonist ICI 182,780. Other researchers
have reported that RSV decreases cell proliferation of both ER-positive and ER-negative
breast cancer cells(Damianaki et al. 2000, Lu and Serrero 1999, Mgbonyebi et al. 1998),
which suggests that the interaction ofRSV with the ER may not fully explain its
inhibitory effect on proliferation.

RSV has both, estrogenic and anti-estrogenic properties when bound to the ER
and therefore has characteristics similar to the selective ER modulators(SERMs),

(Mizutani et al. 2000, Wu et al. 2001, Levenson and Jordan 1999). It has also been
shown that RSV acted as a mixed agonist/antagonist in different mammary cancer cell

lines in the absence of estradiol (E2), but in the presence ofE2,RSV functioned as an antiestrogen.

RSV seems to act like a type I estrogen (estrogens that are sealed into the ligand-

binding domain ofthe ER)whose agonist actions are amplified through a synergistic
interaction of activation function(AF)-1 and -2(Levenson et al 2003).

ERa-positive MCF-7 cells exhibited apoptotic cell death after RSV treatment,

while ERa-negative MDA-MB-231 cells did not(Pozo-Guisado et al 2004), suggesting
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that induction of apoptosis by RSV in human breast cancer cells could be ERa-mediated.
In vascular endotbelial cells, RSV was able to activate a rapid non-genomic

(membrane initiated) activation ofERa and ERp with consequent stimulation of
pbospborylation pathways(Klinge et al. 2005). These effects are mediated by the IGF-IR
pathway(Zhang et al, 2004).

Insulin-Iike Growth Factors

Insulin-like growth factors(IGFs)formerly known as somatomedins, are single
chain polypeptides that have mitogenic or growth promoting properties and have
structural similarity with pro-insulin (Sara and Hall 1990, Rosenfeld et al.1990). IGF-I
and IGF-II share 62% homology in their amino acid sequences. The mature IGF-I and

IGF-II peptides consist of a and p domains that are homologous to the a and p chains of

pro-insulin. Unlike insulin, the IGF peptides remain linked in the mature peptides by C
domains. Both,IGF-I and IGF-II contain an additional short D domain that is not foimd
in insulin. The IGF-I and IGF-II prohormones contain a C-terminal E peptide that is
cleaved in the Golgi apparatus during secretion(Daughaday and Rotwein 1989).

Insulin-like Growth Factor-I(IGF-I)

The IGF-I gene is located on chromosome 12; it consists of six exons and has two

promoter sites(Jansen et al. 1983, Tobin et al. 1990). The results of a series of studies
conducted in animal models, suggested that diet and nutrition might induce different

patterns ofIGF-I transcripts (Pell et al. 1993,Zhang et al. 1997). Translation of pre-proIGF-I can be initiated from codons in exons 1, 2 or 3; alternate polyadenylation sites in

the 3'-untranslated region ofthe molecule also contributes to differences in transcript
22

size. IGF-I transcripts range in size from < 1 kb to 7.5 kb(Adamo et al. 1993).

Alternative splicing ofthe IGF-I gene product generates three different proIGF-I proteins.
These three forms contain 35 to 77 amino acid E-domains, which share a common 16
amino acid N-terminal portion.

Expression of the IGF-I gene is regulated primarily by growth hormone(GH).
Nevertheless, expression ofIGFs is also influenced by various hormones, including

estrogens, adrenocorticotropic hormone, thyrotropin, luteinizing hormone, folliclestimulating hormone(FSH), as well as by other growth factors, such as platelet-derived
growth factor(PDGF),epidermal growth factor(EGF)and fibroblast growth factor
(FGF)(Pell et n/1993, Daughaday and Rotwein 1989, Stewart and Rotwein 1996). Diet
and nutrition affect circulating IGF-I levels, suggesting a possible role in IGF-I
production (Daughaday and Rotwein 1989).

IGF-I has both, immediate and long-term effects on various cellular activities, and
these effects are mediated mainly through the IGF-I receptor(IGF-IR). IGF-I exerts an

acute anabolic action on protein and carbohydrate metabolism by increasing cellular

uptake of amino acids and glucose, and by stimulating glycogen and protein synthesis
(Jones and Clemmons 1995). IGF-I also has a long-term impact on cell proliferation,
differentiation, and apoptosis(Jones and Clemmons 1995). IGF-I is a potent mitogen for

a wide variety of cells and exerts its mitogenic action by increasing DNA synthesis and
by stimulating the expression of cyclin Dl, which accelerates progression ofthe cell
cycle from Gi to S phase (Furlanetto et al. 1994,Dufoumy et al. 1997). The mitogenic
effect ofIGF-I can be abolished by suppressing the expression of cyclin Dl (Kormann et

al. 1998). In addition to stimulating cell cycle progression, IGF-I also inhibits apoptosis.
IGF-I is able to stimulate the expression of Bel proteins and to suppress expression of
23

Bax, which results in an increase in the relative amount ofthe Bel/Bax heterodimer,

thereby blocking initiation ofthe apoptotic pathway(Minshall et al. 1997, Parrizas and
LeRoith 1997, Wang.et a/. 1998).

Insulin-like Growth Factor-II(IGF-II)

The IGF-II gene is located on chromosome 1 lpl5, 1.4 kb downstream from the
insulin gene (Brissenden et al. 1984). The IGF-II gene consists of nine exons, and the
mature peptide is encoded by exons 7,8 and 9. The IGF-II gene is transeribed from four

different promoters(P1-P4). During fetal development,IGF-II expression is much higher
than in the post-natal period or in the adult. A distinct pattern of promoter use correlates
with expression levels during development. In the fetus, promoters P2-P4 are active,
while after birth PI becomes dominant(Sussenback et al. 1993). The IGF-II gene has
parental allele-specific expression, thus it is referred to as an imprinted gene

(Giannoukakis et al. 1993). When loss ofimprinting occurs, biallelic expression ofIGFII results, ultimately leading to over-expression ofthis potent growth factor (Jarrad et al.
1995, Oda et al. 1997, Cui et al. 1998).

IGF-II gene expression is regulated by tumor suppressor genes such as p53, WTl
(Wilms' tumor gene)and GC factor(GCF)(Kitadai et al.1993, Zhang et al. 1996,

Toretsky and Helman 1996). mRNAs transcribed from P1-P4 promoters range in size
from 1.8 kh to 6.0 kb. DNA methylation(Wutz and Barlow 1998), histone acetylation

(Hu et al. 1998) and use of specific promoter sites(Vu and Hoffman 1994, Yun et al.
1998) are mechanisms that may control allele-specific transcription.

The IGF-II gene encodes a single transcript that results in a 156 amino acid
protein, including an 89 amino acid E-domain. ProIGF-II contains sites of0-linked
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glycosylation. ProIGF-II is converted to mature IGF-II by sequential cleavage after
amino acids 104 and 87. Differential glycosylation and cleavage within the E-domain can
therefore result in multiple proIGF-II isoforms.

Concentration ofIGF-II in the blood is higher than IGF-I levels in humans of all

ages. In adults IGF-II levels vary between 400-600 ng/ml whereas IGF-I levels range
between 100-200 ng/ml. IGF-II has mitogenic and anti-apoptotic actions, and regulates

cell proliferation and differentiation. Disruption ofIGF-II gene in mice resulted in
substantial growth retardation (DeChiara et al. 1990). IGF-II also stimulates the
differentiation of neuronal and muscle cells, and plays an important role as an angiogenic

factor(Volpert et al. 1996). IGF-II can suppress apoptosis of mammary epithelial cells
induced by serum withdrawal (Farrelly et al. 1999). It has recently been established that

this is achieved through phosphatidyl inositol 3 kinase(PI3K)and mitogen-activated
protein kinase(MAPK)signals that ultimately inhibit the activity of the pro-apoptotic
protein BAD (Gilmore et al. 2002).

Insulin-like Growth Factor Binding Proteins(IGFBPs)

The actions ofIGFs can be modulated by interactions with a family of six insulin
like growth factor binding proteins(IGFBPs). Their ability to form complexes with IGFs
influences IGFs transport to membrane receptors and thus, also affects IGFs effects on

cell proliferation(McCusker and Clemmons 1992). IGFBP-1 to -6, share 40-60% amino
acid homology. All six IGFBPs have 16-18 conserved cysteine residues in the amino and
carboxy terminal regions. The binding affinities ofthe six IGFBPs are similar for IGF-I

and IGF-II(2-20 and 3-30 XlO^/mol,respectively) with the exception ofIGFBP-6, which
has 20- to 70-fold higher affinity for IGF-II(Zapf 1995). The majority of circulating
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IGFs(>97%)are bound to IGFBPs, predominantly IGFBP-3, whieh has an affinity equal
to or greater than that of the IGF-IR(Clemmons et al. 1990).

The IGFBPs genes share a common structural organization, in which four
conserved exons are located within genes ranging from 5 kb (IGFBP-1)to more than 30

kb (IGFBP-2 and -5)(Baxter 1997). Exon 1 of the IGFBP gene family is shared by

several other genes encoding a variety of proteins, leading to proposals that they might be
members of a larger gene family(Hwa et al 1999, Vilmos et al. 2001).

IGFBP-1

The IGFBP-1 gene is located on chromosome 7pl2-13, and is 5.2 kb in length.
IGFBP-1 is a 25 kDa protein with an Arginine-Glyeine-Aspartic Acid(RGD)sequence in
it carboxy terminus(Shimasaki and Ling 1991). The RGD sequence is recognized by
human integrin receptors in the cell membrane, suggesting an IGF-independent role

through these integrin receptors (Ruoslathi and Pierschlaber 1987). IGFBP-1 is produced
in the liver, decidua, and kidneys and is the most abundant IGFBP in amniotie fluid.

Insulin and eorticosteroid regulate IGFBP-1 levels in serum by transeriptional control of
hepatic sjmthesis(Hasegawa et al. 1995).

IGFBP-2

The IGFBP-2 gene is located on chromosome 2(Allander et al 1993), and is 32

kb in length (Ehrenborg et al. 1991). IGFBP-2 is a 31 kDa protein (Shimasaki andLing

1991) that also has an RGD sequence, but IGFBP-2 has not been demonstrated to bind
integrin-type receptors.

IGFBP-2 concentrations are age-dependent, with the highest levels see during
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infancy and old age, and the lowest levels seen in young adults(Cohen et al. 1995).
IGFBP-2 is the primary IGFBP in cerebrospinal fluid(Bemardini et al. 1994)and is
elevated in certain tumors ofthe central nervous system.(Muller et al. 1994).

Additionally, IGFBP-2 expression is less dependent on insulin and the metabolic rate as
compared to IGFBP-1.

IGFBP-2 is the most abundant IGFBP secreted by estrogen receptor positive

breast cancer cell lines, and its secretion by breast tumors in vivo correlates with estrogen

receptor positivity(Maxwell et al. 1999). Our laboratory has previously reported IGFBP2 in the conditioned media from MCF-7 cells as well as IGFBP-2 mRNA(DeLeon et al.
1990).

IGFBP-3

The IGFBP-3 gene is located on chromosome 7 next to the IGFBP-1 gene

(Allander et al. 1993), and is 8.9 kb in length. IGFBP-3 serum levels are low at birth,
increase during childhood, peak at puberty, and decrease after puberty(Katz et al. 1995).
In vivo, GH is the primary regulator ofIGFBP-3 expression(Katz et al. 1995), while in
vitro, IGFBP-3 can stimulate or inhibit growth in either an IGF-dependent or IGFindependent manner(Murphy et a/. 1995, Nickerson et a/. 1998).

IGFBP-4

The IGFBP-4 gene is located on chromosome 17(Allander et al. 1995). The non-

glycosylated form ofIGFBP-4 has a molecular weight of24 kDa, while the glycosylated
form weights 28 kDa(Katz et al. 1995). IGFBP-4 has been purified from many sources,
which include human osteosarcoma(Mohan et al. 1989, Andress and Bimbaum I99I),
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human prostatic carcinoma (Perkel et al. 1990), and human glioblastoma(CamachoHuber et al. 1992). In bone,IGFBP-4 is regulated by vitamin D and PTH(Mohan et al.
1995, Seharla et al. 1991).

Like IGFBP-2, elevated IGFBP-4 expression in leukemie T cells is affected by

the autocrine/paracrine aetion ofIGF-II, but not by IGF-IR expression (Elminger et al.
1998). Overexpression and protein secretion ofIGFBP-4 has been reported in breast
caneer cells(De Leon et al. 1990, Adamo et al. 1992). Yet unlike IGFBP-2,IGFBP-4

expression in breast eancer does not correlate with estrogen receptor status, sinee both
ER-positive and ER-negative eells secrete IGFBP-4(Maxwell et al. 1993, Oh et al.
1996).

IGFBP-5

The IGFBP-5 gene is located on ehromosome 2, and its moleeular weight ranges
from 29 kDa to 32 kDa depending on glyeosylation status. In smooth muscle eells,
IGFBP-5 interact specifically with two extracellular matrix proteins(ECM),

thrombospondin-1 and osteopontin, whieh not only potentiate the IGF-I effeet but may
modulate the eooperative interaetion between the IGF-IR and integrin reeeptor pathways
(Nam et al. 2000). IGFBP-5 is thought to act as a depot for IGF-II in bone via its high
affinity for ECM proteins and hydroxyapatite, the mineral eonstituent of bone, and

potentiates the proliferative aetions ofIGF-II on osteoblastie cells (Bautista et al. 1991,
Miyakoshi et al. 2001).

IGFBP-6

The IGFBP-6 gene is loeated on ehromosome 12, and the G-glycosylated protein
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weights 34 kDa(Allander et al. 1993, Cohen and Rosenfeld 1995). Human IGFBP-6 is
primarily found in CSF and serum (Katz et al. 1995). IGFBP-6 is the only IGFBP that
has higher affinity for IGF-Il than for IGF-1(Baxter et al. 1992, Bach et al. 1993,
Clausen et al. 1995). lGFBP-6 expression is regulated by lGF-11. Furthermore, only

estrogen receptor-negative breast carcinoma cell lines produced IGFBP-6. In these breast
carcinoma cell lines, IGFBP-6 expression was enhanced by retinoic acid, but was not
affected by IGF-I(Shiekh et al. 1993).

IGF Receptors

Both, the IGF-I and IGF-II receptors are glycoproteins that are located on the cell
membrane. The two receptors, however, differ completely in structure and function
(LeRoith et al. 1995, Stewart and Rotwein 1996).

IGF-IReceptor(IGF-IR)

The IGF-IR gene is located on chromosome 15p25-26, it has a size of 100 kb, and
consists of21 exons. IGF-IR is a tetramer oftwo identical a-subunits(706 amino acids)

and two identical P-subunits(626 amino acids)(Stewart and Rotwein 1996, SeppLorenzino 1998). The a-subunits are extracellular and form the ligand-binding domain.

The two P-subunits, which contain short extracellular and transmembrane segments and a
larger intracellular segment, transmit the ligand-induced signal. The p-subunit has three
domains: a tyrosine kinase domain; a juxtamembrane domain, which has motifs required
for recruiting the major signaling adapter proteins, like insulin receptor substrate(IRS)
and Src/collagen homology proteins(SHC); and the carboxyl terminal domain, which has
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several important residues for IGFs signaling. These residues in the carboxyl-terminal
domain are required for binding various signaling proteins, like growth faetor receptor-

bound protein 10(Grb-10), 14-3-3-epsilon (Ogihara et al. 1997), p85 subunit of

phosphatidyl inositol 3' kinase (PI3K), and SHPTP2(Hongo et al. 1996, Sepp-Lorenzino
1998). Specific residues ofthe IGF-IR, which mediate mitogenesis, transformation and
anti-apoptotic functions ofthe IGFs, that are important for malignant phenotype have
been identified (Miura et al. 1995, O'Connor et al. 1997).
When IGF-I or IGF-II binds to the extracellular subunit ofthe IGF-IR, a

conformational change is induced in the transmembrane P-subunits, resulting in

autophosphorylation ofthe eytoplasmie tyrosine kinase domain ofthe P-subunit. This

fully activates the receptor tyrosine kinase, which then autophosphorylates additional
tyrosine residues in the juxtamembrane and carboxyl-terminal domains flanking the
tyrosine kinase domain. These phosphorylated residues (particularly tyrosine 950), can
then function as docking sites for the IRS and She adaptor proteins. Phosphorylation of

these adaptor proteins allows them to recruit other factors, such as Grb/SOS and the p85

regulatory subunit of phosphatidyl inositol 3' kinase (PI3K), thereby leading to activation
of the (mitogen activated protein) MAP kinase and PI3K cascades. The ultimate targets
ofthe MAPK and PI3K pathways include members ofthe Ets and forkhead transcription

factors families. Regulation oftranscription factors provides a mechanism by which IGF
action at the cell surface can elicit changes in gene expression that eventually mediate the

proliferative, differentiation, and apoptotie effects ofIGFs(LeRoith et al. 1995).

IGF-IIReceptor(IGF-IIR or M6P/IGF-IIR)

The IGF-IIR gene is located on chromosome 6q25-27, and is 140 kb in size. The
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IGF-IIR is monomeric(Morgan et al. 1987, Oshima et al. 1988, Gates et al. 1998).
Three ligand-binding regions are found in the extracellular domain ofthe receptor, one

for IGF-II binding and two for protein containing mannose-6-phosphate(M6P),including

renin, proliferin, thyroglobulin, and the latent form oftransforming growth factor(TGF)P (Jones and Clemmons 1995). Binding ofthe IGF-IIR to TGF-P activates the latter
(Gates et al. 1998, Braulke 1999). Since IGF-IIR can bind both, IGF-II and M6P-

containing molecules, it is also called the IGF-II/M6P receptor. The IGF-IIR is also
involved in targeting of proteins to the lysosomes and may play a role in degradation of
the extracellular matrix. There is also some evidence that interactions ofIGF-IIR with

mannose 6-phosphate-bearing proteins may increase breast tumor angiogenesis

(Rasmussen and Cullen 1998). Although the binding sites for lysosomal enzymes and
IGF-II are distinct, reciprocal inhibition between the ligands has been observed (Kiess et

al. 1989). When M6P proteins bind, IGF-II binding is decreased, possibly due to steric
hindrance or conformational changes in the IGF-IIR(Vignon and Roehefort 1992). In
MCF-7 cells an extracellular reciprocal interaction exists between IGF-II and Cathepsin

D at the IGF-IIR. IGF-II inhibited 55% of'^^I-eathepsin D binding to the IGF-IIR
(Mathieu et al. 1990). Little is known about the regulation ofIGF-IIR expression,

although some studies have suggested that insulin, IGFs,EGF,and M6P may increase the
level ofIGF-IIR in the cell membrane (Jones and Clemmons 1995, Stewart and Rotwein
1996, Hoeflich et al. 1996, Takigawa et al. 1997). IGF-IIR has no tyrosine kinase

activity, and since binding ofIGF-II to the IGF-IIR results in degradation ofIGF-II,
IGF-IIR acts like an antagonist to IGF-II, reducing its biological activity(Gates et al.

1998). Because ofthis effect, IGF-IIR has been considered to be a potential tumor

suppressor molecule. A unique feature of the IGF-IIR may contribute to its ability to act
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as a scavenger for eireulating IGF-II: upon proteolytic eleavage, the extraeellular domain
ofthe reeeptor is dissociated from the cell membrane as a soluble fragment that cireulates
in the blood with the ability to bind to IGF-II and to faeilitate its degradation (Kiess et al.
1987, MacDonald et al 1989, Valenzano et al 1995,Zaina and Squire, 1998, Costello et

al 1999). Under normal physiological conditions, there is an equilibrium and rapid
movement in the eycling ofthe IGF-llR between the cell surface and internal organelles.
However, abnormalities anywhere in the traffieking may have major eonsequences in
normal cellular function and organism survival. In the human lysosomal storage disorder

(L eell disease), a deficiency in the enzyme N-acetylglueosamine phosphotransferase

usually results in the death of the affeeted person as a result ofthe inability of hydrolases
to be traffieked to lysosomal eompartments (Storrie and Desjardins 1996). However,this
defective-traffieking disorder is not associated with an increased rate of malignancy.

Since malignancy is not a characteristic ofthis disease, defective IGF-llR-mediated
trafficking of M6P proteins does not initiate malignant transformation, hut may
eontribute to tumor progression.
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IGF-II, Cathepsin D and the IGF-II/MdP Receptor Interactions

2

tissue remodeling? \

[lys. enz

tumor spread? I

IGF

ysosome

GF f!
ys. enz

Goigi

Figure 1. High levels ofIGF-II compete with cathepsin D(CD)for biding to the IGFII/M6P receptor. The IGF-II/M6PR binds both IGF-II and CD,which have separate
binding sites. It targets lysosomal enzymes to lysosomes and also functions in the control
of extracellular IGF-II levels.(I)Competition of both ligands in the Golgi;(2)IGF-II
inhibition ofCD uptake at the extracellular level.
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Insulin Receptor(IR)

The IR gene is located on chromosome 19pl3.3-pl3.2. IR is a transmembrane

glycoprotein that mediates the pleiotropic actions ofinsulin. The homodimeric IR exists
in two isoforms that arise from the alternative splicing of exon 11 in the IR mRNA (Seino

and Bell 1989). Exon 11 codes for 12 amino acids (residues 717-728)that are inserted

upstream of the 3'^'^ last residue ofthe extracellular a-subunits ofthe IR-B isoform. The
IR-A (or IR exon 11-)isoform lacks these 12 amino acids. The presence or absence ofthe
exon 11 encoded peptide yields two receptors with unique biochemical properties.

Although both isoforms have similar affinity for insulin, the IR-A binds IGF-II with over
ten-fold higher affinity than the IR-B (McClain 1991, Yamaguchi et at. 1991, Frasca et

al. 1999). The two IR isoforms also display differential kinase activity (Kellerer et al.
1992). The IR-A isoform exhibits a more rapid interhalization and higher recycling rate
than the IR-B (Vogt et al. 1991). The isoforms localize to different regions ofthe plasma
membrane(Uhles et al. 2003).

The high affinity interaction ofthe IR-A with IGF-II(mediated through IGF-II C
and D domains), but not IGF-I, is important for normal fetal and cancer growth (Denley

et al. 2003). Mouse knockout models suggest that while the developmental growthpromoting activities ofIGF-I are exclusively mediated through the IGF-IR,IGF-II can

stimulate growth via not only the IGF-IR but also the IR(Louvi et al. 1997). Cancer cells
expressing the IR-A migrate and are protected from apoptosis by exposure to IGF-II but
not when exposed to the same level ofIGF-I(Sciaeca et al. 2002). IGF-II is

overexpressed by many cancer cells such as breast cancer(Quinn et al. 1996), and
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colorectal cancer cells(Renehan et al. 2000), which also express the IR-A as the
predominant IR isoform.
In IGF-IR deficient murine fibroblasts transfected with the human IR-A,IGF-II

was a more potent mitogen than insulin (Frasca et al 1999). Similar findings were
observed in SKUT-1 human radbdomyosarcoma eells(which lack IGF-IR). In these cells

IGF-II was significantly more potent than insulin in stimulating the Shc/ERK pathway,
while insulin was more potent than IGF-II in stimulating the IRS-l/PDIC/Akt pathway.
As a result, IGF-II was more potent than insulin in inducing cell invasion, while insulin

was slightly more effective in apoptosis protection. IGF-II binds to the IR-A with high
affinity in both, human breast cancer cell lines and human breast cancer specimens,

stimulating the receptor tyrosine kinase activity and leading to mitogenesis. Moreover, in
certain breast cancers(MDA-MB-157 cells and node-negative breast cancers), IGF-II

predominantly signals via the IR rather than via the IGF-IR (Sciacca et al 1999).

Hybrid Receptors

The complexity ofIGF signaling is increased by the formation of hybrid receptors
that result from the dimerization ofIGF-IR and IR hemi-receptors. Each hybrid receptor

consists of a single a and P subunit linked by disulfide bonds, which are formed in the

Golgi apparatus of cells expressing both the IGF-IR and the IR. This could be due to the
preferential formation of disulfide bonds between cysteine residues in IGF-IR and IR
subunits themselves. Thus, in some circumstances, hybrid receptors may outnumber

homoreceptor molecules at the cell surface. Hybrid receptors retain high affinity for
IGFs, but exhibit a dramatically decreased affinity for insulin. Thus,the presence of a

significant number of hybrid receptors may selectively diminish cellular responsiveness
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to insulin, but not to IGFs. The effects of hybrid receptors are further complicated by the

presence ofthe IR-A and IR-B isoforms and their different IGF-II binding characteristics.
Therefore, the relative expression ofthe IGF-IR and IR genes and the degree of
alternative splicing of exon 11 ofthe IR gene governs the ability of a given cell to
respond to IGF-I, IGF-II, and insulin.
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Table 1. Molecular Features of Members of the IGF Family

Molecular

No. of amino

Gene

Gene

No. of

weight, kDa

acids

location

size, kb

exons

IGF-I

7.7

70

12q22I2q24

100

6

IGF-II

7.5

67

IlpI5

30

9

15q2515q26

100

21

Glycoprotein

a-subunit:
IGF-IRf

225

706

b-subunit;
626
IGF-IIR

270

2450

6q25-6q27

140

48

IGFBP-1

25.3

234

7pl2-7pI4

5.2

4

IGFBP-2

31.4

289

2q3I-2q34

32

4

IGFBP-3

28.7

264

7pI2-7pI4

8.9

5

12

4

IGFBP-4

26.0

237

I7qI2I7q2I

IGFBP-5

28.6

252

2q31-2q24

33

4

IGFBP-6

22.8

216

12qI3

4.7

4

Abbreviations used: IGF = insulin-like growth factor; IGFBP = insulin-like growth
factor-binding protein; IGF-IR = IGF-I receptor; IGR-IIR = IGF-II receptor; kb =
kilobases; kDa = kilodaltons.

tIGF-IR is a tetrameric protein(two «- and two 13-subunits).
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IGF-II, breast cancer and cell survival

Mechanisms ofIGF-II Over-expression and Preferential Promoter Usage
Increased levels oflGF-11 in the micro-environment of a tumor can be potentially

aecomplished by multiple mechanisms including:(1)loss ofimprinting(LOl) where
lGF-11, whieh is normally expressed from the paternal allele, is now expressed from both

alleles, maternal and paternal(Ogawa et al. 1993, Rainier et al. 1993, Zhan et at. 1994);

(2)loss of heterozygosity (LOH)with paternal duplication, where lGF-11 transeription
oeeurs from two eopies instead of one eopy of a gene, leading to higher mRNA levels;

(3)Loss of transcriptional suppressors. A possible suppressor candidate could be the
Wilms' tumor-1 protein(WT-1). WT-1 protein has been shown to bind to sites within the

lGF-11 promoter-3 (P3), and decrease lGF-11 transeription(Drummond et al. 1992). The
tumor suppressor gene p53 may function to suppress lGF-11 activity through direct
inhibition oftranscription(Zhang et al. 1996)or by induction oflGFBP-3(Buckbinder et
al. 1995). Thus, mutations of p53,found in many tumors, may also contribute to
inereased lGF-11 expression.(4)lGF-11 over-expression may also occur through
excessive transcription due to the activation oftranscription factors that positively
regulate lGF-11.

lGF-11 gene promoter activation is highly variable in malignant and benign breast,

prostate and bladder tissues. While a majority of tumor samples utilized three promoters,
P2-P4, in a variety of combinations, when quantitated, P3 and P4 promoters where much
more active than P2(Mineo et al. 2000).
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IGF-II-Induced Malignant Transformation

Studies from transgenic mice over-expressing IGF-II, and IGF-II knockout mice
indicate that this growth factor plays an important role in normal biology and malignant
transformation of breast epithelial cells. Mice over-expressing IGF-II in the mammary

gland under the control ofthe sheep P-lactoglobulin promoter elements, showed
mammary tumor formation (Bates et al. 1995). Mice from four different transgenic lines
over-expressing IGF-II developed mammary tumors. While IGF-II over-expression does
not cause malignant tumor growth in some other organs such as uterus(Ward et al.
1994), in the mammary gland excess IGF-II contributes to tumor formation. This
provides evidence for the role ofIGF-II signaling in malignant transformation.
In breast cancer, IGF-II is expressed in the stroma(Giani et al. 1996) but can also
be found in the malignant breast epithelial cells(Paik 1992). IGF-II plays a role in
malignant transformation, and is important in the maintenance ofthe malignant

phenotype. In addition, it has been shown that malignant breast epithelial cells can induce
expression ofIGF-II in the stroma in vitro (Singer et al. 1995).

IGF-II and Cell Migration

Altered contact between cells and their associated extracellular matrix(ECM)is a

prerequisite for breast cancer cell migration and thus metastasis(Gui et al. 1997). Cell
migration requires interactions with adhesive molecules, such as vitronectin(VN);
indeed, interaction of cells with VN has been reported to be essential for IGF-stimulated

migration (Stewart et al. 1990, Jones et al. 1996, Doerr and Jones 1996, Clemmons et al.
1999). VN binds directly to IGF-II(Upton et al. 1999). IGF-II has been demonstrated to
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stimulate increased migration in breast carcinoma cells (Jones et al. 1996). One

mechanism through which this has been hj'pothesized to occur is by increased avp3integrin expression(VN receptor), thus facilitating an increased interaction with VN in
the ECM. Studies examining functional interactions between VN and the IGF system

demonstrate that VN and IGFs are tightly regulated and closely associated. This is

illustrated by demonstration that occupancy of both, the avPs-VN receptor and the IGF-

IR are prerequisites for cell cancer migration (Jones et al. 1996, Doerr and Jones 1996,

Zhang and Clemmons 1998), and by the finding that IRS-1, a downstream target ofIGFIR, associates with the VN receptors, the av-integrins(Vuori and Roushlathi 1994).
The IGF-II-VN complex can stimulate migration of MCF-7 cells, this effect may

in part, be attributable to reduced interactions with the IGF-IIR(Noble et al. 2003).

IGF-II, Estradiol and Estrogen Receptor(ER)Interactions

IGF-IR and ER are co-expressed in some breast cancer cells, and there is a complex
crosstalk between the two pathways(Yee and Lee 2000). This crosstalk is of particular

importance to breast cancer since ER is known to be a strong prognostic factor for breast
cancer growth and anti-estrogens such as tamoxifen are widely used in treating the
disease. In vitro, ER-positive breast cancer cells(MCF-7,T47D and ZR-75)can be

stimulated to proliferate by pico- or nanomolar concentrations ofIGF-II(Karey and
Sirbasku 1988), while ER-negative cells(MBA-MB-231, MDA-435)are only minimally
responsive or are not stimulated to proliferate by the IGFs. Furthermore, a synergy occurs
between estradiol and IGF-I in mediating the proliferative response in ER-positive cells

(Stewart et al. 1992). An explanation for this effect may be that the expression of nearly
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all members ofthe IGF system is under transcriptional control ofthe ER. Thus, the ER

regulates the transcription ofIGF-I(Umayahara et al. 1994), IGF-II(Osbome et al. 1989,
Lee et al 1992),IGF-IR (Stewart et al 1992),IGFBPs(McGuire et al 1992) and IRS-1
(Lee et al 1999, Salerno et al 1999, Molloy et al 2000).

IGFs have also been reported to activate the ER. Estrogen is able to bind the ERa

in the cytosol, which then interacts with the adapter proteins She or p85a ofPI3-kinase.
Both Shc/ER and PI3K/ER complexes can further form a ternary complex with IGF-IR
on the cell membrane,leading to translocation ofthe ER to the region ofthe cell
membrane and activation ofthe IGF-IR-dependent MAP-kinase or PI3K/Akt pathways

inducing cell proliferation and prevention of apoptosis(Zhang et al, 2004).

IGF-II and Apoptosis

Programmed cell death(PCD)or apoptosis, constitutes a system for the removal
ofunnecessary, aged, or damaged cells that is regulated by the interplay of pro-apoptotic
and anti-apoptotic proteins.

Protection from apoptosis by IGFs is mediated by activation ofPI3K and the

Akt/protein kinase B(PKB)pathway(Kulik et al 1997, Peruzzi et al 1999) Akt/PKB
phosphorylates BAD,a member ofthe Bcl-2 family of pro-apoptotic proteins(Datta et al

1997, 2000); phosphorylated BAD cannot heterodimerize with Bcl-2 or Bc1-Xl, remains

in the cytosol and does not promote cell death(Zha et al. 1996). It has been reported that
IGFs can also mediate their anti-apoptotic effect by other pathways that do not involve

BAD (Kulik and Weber 1998). Thus,IGFs can protect cells from apoptosis by multiple
signaling pathways.

The IGF-IIR also plays an important role in the IGF-II mediated effect on
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apoptosis. One study found cancer-related missense mutations in the IGF-IIR gene with
resultant disruption ofthe binding ofIGF-IIR to its ligand. Cancer cells that lack the
ability to degrade IGF-II have been shown to have strong growth potency(Byrd et al.
1999). Suppressing the expression ofIGF-IIR yields the same effect as mutation in the
IGF-IIR gene(CGorman et al 1999). Reestablishing the function ofIGF-IIR in cancer
cells that lack IGF-IIR reduces cancer growth and increases apoptosis(Souza et al
1999).

IGF-II specifically, has been found to protect cancer cell from apoptosis induced
by different mechanisms. Endogenous or exogenous IGF-II addition to C2CI2 mouse

myoblasts caused protection from cisplatin-induced apoptosis. This effect was associated
with an increase in p70 ribosomal protein S6 kinase(p70S6K, which plays a critical role
in cell growth) basal activity(Wan and Helman 2002). IGF-II has also been shown to
induce a delay in mammary involution in vivo in the IGF-II transgenic mouse model. In
this study the delayed mammary involution resulted from a significant reduction in

mammary epithelial apoptosis, and not from increased cell proliferation. This effect
correlated with prolonged Akt/PKB phosphorylation. In a different study, IGF-II

significantly reduced retinoic acid(RA)-induced apoptosis of keratinocytes, whereas
IGF-I and insulin did not. The inhibition ofRA action by IGF-II was independent of its

ability to signal through the IGF-IR or to interact with IGFBPs(Louafi et al 2003).

Cathepsin D and the M6P/IGF-IIR

The human Cathepsin D gene contains nine exons and is located in chromosome

1 lpl5 (Augereau et al 1988, Redecker et al 1991), and expresses a 2.2 kb transcript.

Cathepsin D is synthesized as preprocathepsin D (pCD). Upon entering into an acidic
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lysosome, the single chain proeathepsin D(52 kDa)is activated to CD (51 kDa)and
further processed and glycosylated into several distinct forms(51-14 kDa). For more

than a decade, over-expression and secretion of Cathepsin D(CD)by breast cancer cells
have been associated with increased risk ofrelapse and metastasis(Rochefort et al. 1987,

Thorpe et al. 1989, Spyratos et al. 1989). The mechanism by which CD increases the
incidence of clinical metastasis involves increased cell growth rather than escape of

cancer cells through the basement membrane. The fundamental role of CD is to degrade
intracellular and internalized proteins(Dingle et al. 1973). CD has been suggested to take
part in antigen processing (Williams and Smith 1993), and in enzjmiatic generation of
peptides hormones. CD is catalytically active at acidic pH values that vary according to
substrates, but is mostly found in intracellular vesicles, lysosomes, phagosomes and late

endosomes. CD is a lysosomal protease regulated by estrogens in ER-positive cells, but
secreted eonstitutively by ER-negative cell lines. The proportion of pCD secreted by
human breast cancer cell lines has been shown to correlate with their invasive potential

(Couissi et al. 1997). Normally, the newly synthesized soluble lysosomal enzymes, such
as pCD,are post-translationally modified to contain M6P residues on their N-linked
oligosaecharides. The acquired M6P residues enable the enzymes to bind to M6P
receptors(IGF-II/M6PR)in the Trans Golgi network(TGN). The receptors and their

ligands cluster into transport vesicles and travel to an acidic pre-lysosomal compartment
where the low pH causes dissociation of the receptor-ligand complex. The free M6P

receptors can travel to the plasma membrane or back to the Golgi to reinitiate another
cycle of biosynthetic enzyme transport. In the absence of M6P receptors, most M6P-

containing glycoproteins are secreted from the cell. The IGF-II/M6PR is mainly localized
in the intracellular compartments(90%), with 10% ofthe receptor being present on the
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cell surface(Komfeld 1992).
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CHAPTER THREE

MATERIAL AND METHODS

Cell culture

MCF-7, T47D,Hs478t breast carcinoma cell lines and MCF-lOA breast epithelial

cells were obtained from the American Type Culture Collection(ATCC). MCF-7 cells

were maintained in a 5% C02 incubator at 37''C, using DMEM/F12 media(Cellgro)
supplemented with 10 ml of 5,000 units penicillin/streptomycin(100 units/ml penicillin
and 100 units/ml streptomycin sulfate, Cellgro),4niM L-glutamine (Cellgro), 3 pg/ml Pamphotericin, and 5% fetal bovine serum (Hyclone). T47D cells were grown in RPMI1640 media supplemented with 10 pg/ml insulin, 2mM L-glutamine (Cellgro), 5,000

units penicillin/streptomycin(100 units/ml penicillin and 100 units/ml streptomycin
sulfate, Cellgro) and 10% fetal bovine serum (Hyclone). Hs578t DMEM media was
supplemented with O.Olmg/ml bovine insulin (Sigma), 10% fetal bovine serum

(Hyclone),4niM L-glutamine (Cellgro) and 10 ml of 5,000 units penicillin/streptomycin
(100 units/ml penicillin and 100 units/ml streptomycin sulfate, Cellgro). MCF-10

DMEM/F12 media was supplemented with 10 ml of 5,000 units penicillin/streptomycin
(100 units/ml penicillin and 100 units/ml streptomycin sulfate, Cellgro),4mM L-

glutamine (Cellgro), 3 pg/ml P-amphotericin, 10 pg/ml insulin (Sigma), 0.5 pg/ml

hydrocortisone (Sigma), murine epidermal growth factor(EGF)20 ng/ml(GIBCO-BRL),
cholera toxin lOOng/ml(Sigma)and 5% equine serum. Cells were detached by
trypsinization(Ix Trypsin EDTA,Cellgro). Recombinant human precursor lGF-11

(prolGF-11, aa 1-156) was purchased from GroPep (Adelaide, Australia). Resveratrol was
purchased from Sigma Chemical Co.(St. Louis, MO),and dissolved in dimethyl
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sulfoxide(DMSO,Fischer Scientific, Pittsburgh,PA). Media from RSV treated cells

(CM)was collected(24 and 48 hrs), centrifuged(800 rpm for 5min)and frozen(-20®C)
until assayed. Cell lysates from RSV treated cells(CL)was collected,(3,6 hrs),

centrifuged(800 rpm for 5min), and frozen (-20'^C) until assayed.

Western blot analysis

Total protein concentration(30 pg)of serum free medium(SFM)collected after

24 and 48 hrs ofRSV treatment (10"^-10"'^) and control group(SFM with vehicle) or(3-5
pg)of cell lysates collected after 3 and 6 hrs ofRSV treatment, was used to load 10-20%
polyaerylamide-SDS gradient gels and transferred to a nitrocellulose membrane Bio-

Trace'^NT (Life Sciences, Ann Arbor, MI)using a Semi-Dry electrophoretic Transfer
Cell(Bio-Rad Laboratories, Hercules, CA). Protein concentration was measured using

the Coomassie Plus Protein Assay Reagent^"^(Pierce Biotechnology, Rockford,IL)
Nitrocellulose membranes were blocked with 2% BSA IgG free(Sigma Chemical Co.,

St. Louis, MO)in PBS/0.05% Tween for 2 hrs. Membranes were then incubated with
Amano IGF-II monoclonal antibody, clone S1-F2(1:1000 Amano, Mitsubishi, Troy,

VA). The Amano antibody is able to detect both the mature and the precursor forms of
IGF-II. Similarly, the IGF-I polyclonal antibody (1:1000, Oncogene Research Products,

San Diego, CA)was used to detect IGF-I. Cathepsin D antiserum (1:400) was used to
detect CD immunoreactive bands. Membranes were also incubated with anti-Bcl-2

monoclonal antibody(Santa Cruz Biotechnology, CA), anti-survivin polyclonal antibody

(Novus Biologicals, Littleton, CO),and incubated at 4'^C overnight. The blots were also
probed with P-actin antibody (1:10,000, Sigma Chemical Co., St. Louis, MO)and used as
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a protein loading control. After 3x10 min washes in PBS/0.05% Tween,the
corresponding secondary antibodies(1:1000, Amersham, Arlington Heights, IL) were
added to the membranes(1 hr at RT),followed by 3 x 10 min washes and HRP (1:1000

Amersham, Arlington Heights, IL). Protein visualization was achieved by using enhanced
chemiluminescence(ECL)and autoradiography with Hyperfilm ECL film (Amersham,

Arlington Heights, IL). The signals on the x-ray films were quantified using

Chemilmager™ 4000(Alpha Innotech Corporation).

Northern blot analysis

Total RNA was extracted using Tri Reagent™(Molecular Research Center), after
12 and 24 hrs incubation of MCF-7 and MCF-IOA cells in serum free media(SFM),in

the presence of 10'^ or lO'"^ M RSV. RNA was then precipitated using isopropanol and
solubilized in 0.5% SDS. 10 pg of each sample RNA was then electrophoresed on a 1%

agarose-formaldehyde gel, and transferred to a nylon membrane(Hybond™-N,
Amersham, Arlington Heights, IL)followed by UV cross-linking. The membranes were

pre-hybridized (Clontech expressHyb™ solution) for 1 hr at 68®C, before ^^P-labeled
IGF-II cDNA or CD cDNA was added. Blots were hybridized at 42''C. The membranes

were then washed and exposed to Kodak film with intensifying screens at -SO^'C for 2-3

days. Subsequently, the membranes were stripped and reprobed with ^^P-labeled
cyclophilin cDNA, which was used as a loading control. The signals were quantitated

using densitometric analysis ofthe autoradiographs by Chemilmager ™ 4000(Alpha
Innotech Corporation).
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Cell growth studies

Cell growth was measured by bromodeoxyuridine(BrdU)incorporation assay
(Oneogene Research Products, San Diego CA), after 24 and 48 brs ofRSV treatment.

MCF-7 cells (IxlO'^/well) were plated in 96 well tissue culture plates and grown in serum

free medium(SFM). After 6 brs incubation, 10"^ M or 10""* M RSV was added to the
wells.

Cells were then incubated with BrdU label for 20 brs(5% CO2,37^C incubator). BrdU
incorporation was detected immunocbemically,following partial denaturation of double
stranded DNA.In this assay, borseradisb-peroxidase(HRP)catalyzes the conversion of
the cbromogenic substrate tetra-metbylbenzidine(TMB)to a blue solution, the intensity

of which is proportional to the amount of incorporated BrdU in the cells. The colored
reaction product is then quantified using a spectropbotometer(405-595 nm). To evaluate
at what extent the concentration-dependent effect ofRSV on cell growth was due to IGF-

II, BrdU incorporation was measured in the presence of2 pg/ml anti-IGF-IR antibody
(Santa Cruz Biotechnology), which inhibits binding as well as basal and IGF-I / IGF-II
stimulated DNA synthesis. The effect of different concentrations of proIGF-II(10-

lOOng/ml)on RSV (10""^ M)treated MCF-7 cells was also assessed by BrdU
incorporation, after 24 and 48 brs.

Cell viability assay

Cell viability was measured by the 3-[4,5-dimetbyltbiazol2-yl]-2,5-

dipbenyltetrazolium bromide(MTT)assay; cells (IxlO'^/well) were seeded in 96 well
plates, and grown in serum free medium. Cell viability(MCF-7, MCF-10,T47D and
Hs578t cells) was assessed at 24 and 48 brs, by measuring the rate oftetrazolium salts
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reduction to formazan(MTT,Sigma Chemical Co., St. Louis MO), which is proportional
to the number of living cells. At the end of incubation, the absorbance was read at 540
nm. To evaluate at what extent the concentration dependent effect ofresveratrol on cell

survival is due to proIGF-II signaling through the IGF-IR, parallel wells containing

MCF-7 cells treated with 10"^ M RSV, were incubated simultaneously with 2 pg/ml of

anti-IGF-IR antibody. Cell viability was also measured in MCF-7 cells (IxlO^'/well)
transfected with the mature or the precursor form ofIGF-II were seeded in 96 well plates,
and grown in serum free medium. Cell viability was assessed at 24 and 48 hrs, by

measuring the rate of tetrazolium salt reduction to formazan(MTT,Sigma Chemical Co.,
St. Louis MO), which is proportional to the number ofliving cells. At the end of
incubation, the absorbance was read at 540 nm.

Cathepsin D antibodies

Cathepsin D was purified from human placenta according to the method of Takahashi
and Tang, except that a Concanavalin A-Sepharose column purification step was used
before affinity chromatography on Pepstatin-Sepharose. Analysis of protein purity by
sodium dodecyl sulfate/polyacrylamide gel electrophoresis(SDS/PAGE)confirmed the
presence of a major band of30 kDa and a minor band of 14 kDa (visualized by silver and

Coomassie blue staining ofthe gel) Two rabbits(# 4607 and 4608) were immunized with

this preparation of Cathepsin D. Sera was collected and titered by immunoprecipitation of
Cathepsin D as described by our laboratory.

Construction ofvectors

The human IGF-II(cDNA)was kindly provided by Dr. Graeme I Bell(Howard
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Hughes Medical Institute, University of Chicago). The sense precursor IGF-II was

generated by PGR and cloned into the HindOl-Xbal site ofthe pRc/CMV vector
(Invitrogen, San Diego, CA)as previously detailed(DeLeon et al, 1999).

Transfection ofMCF-7, Hs578t and MCF-1OA cells with IGF-IIsense cDNA
MCF-7, Hs578t and MCF-lOA cells were transfected with the sense IGF-II

vector. Transfection was carried out by the liposome method(DOTAP,Boehringer).

G418 (Geneticin, 560 pg/ml) was used to maintain stable transfectants, which were
cloned by limiting dilution in 96 well plates. To identify sense clones, serum-free CM

from 96 well plates was screened with a dot blot assay, which measures IGF-II without
interference by IGF binding proteins(DeLeon et al, 1997).

Real Time PGR

One Step SYBR real-time RT-PCR was performed to assess Bcl-2 and survivin

expression in RSV (10""^) treated cells, using the following primers: Bcl-2-F(ATG TGT
GTG GAG AGC GTC AAC C-3'), Bcl-2-R(AGC GAG GAG AAA TCA AAC AGA

GG-3'), survivin-F(TCA AGG AGC AGC GGA TGT GTA G-3'0, survivin-R(TGA
AGC AGA AGA AAC ACT GGG G-3')PGR amplifications were performed using the

iCycler(BIO-RAD). Reactions were performed in a mixture consisting of a 50 pL
volume solution containing IX SYBR Green supermix PGR buffer(BIO-RAD),

{lOOmM KGL,6 mM MgG12,40mM Tris-HGL,PH 8.4,.4mM of each dNTP(dATP,
dCTP,dGTP and dTTP),iTaq DNA Polymerase 50 U/mL,SYBR Green I, 20mM

Fluorescein,} 300 nM of each primer, 0.25U/mL MultiScribe Reverse Transcriptase

(Promega)and 0.4U/mL Rnase Inhibitor(Promega). The RT-PGR protocol starts with 30
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min at 42°C for the RT. Prior to the PGR step, iTaq DNA polymerase activation at 95 °C

for 10 min was performed. Followed by 30 s denaturation at 95 °C, 15 s annealing at 57
°C and 1.5 min elongation at 72 °C for 40 cycles. Fluorescence was detected at the end of
every 72°C extension phase. To exclude the contamination of unspecific PGR products
such as primer dimers, melting curve analysis was applied to all final PGR products after
the cycling protocol.

Caspase activation assay

MGF-7 cells (IxlO"^ cells/well) were seeded in 96 well plates and incubated

overnight at 37 ^C. The following day RSV (lO""* M)alone or in combination with IGF-II
(mature or precursor forms, 100 ng/ml) was added to the cells for 3 or 6 hrs, followed by
addition of50 pi of caspase assay buffer(150mM HEPES,450 mM NaGl, 150 mM KGl,
30 mM MgGli,1.2 mM EGTA, 1.5% Nonidet P40,0.3% GHAPS,30% sucrose, 150 pM
DEVD-AMG,30 mM DTT,3.0 mM PMSF). Gaspase activity was measured by reading

proteolytically released fluorochrome from the DEVD-AMG substrate using a plate
reading fluorometer with an excitation at 360 nm and an emission at 460 nm.

Mitochondrial membrane potential assessment using JC-1

JG-1 was used for the investigation of mitochondrial membrane depolarization that

occurs in the initial stages of apoptosis. JG-1 is a lipophilic fluorochrome (5,5',6,6'tetrachloro-l,r,3,3'-tetraethyl benzimidazol carbocyanine iodide)that stands for 1st J-

aggregate-forming cationic dye found to be sensitive to the Av|/. The fluorescence

emission spectrum of JG-1 is dependent on its concentration, which in turn, is determined
by the status of the Av|/. JG-1 forms monomers at low dye concentrations, and aggregates
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at higher concentrations. The A\j/ of normal, healthy mitochondria is polarized and JC-1
is rapidly taken up hy such mitochondria. This uptake increases the concentration

gradient of JC-1 leading to the formation of JC-1 aggregates(known as J-aggregates)
within the mitochondria. JC-1 aggregates show a red spectral shift resulting in higher
levels ofred fluorescence emission that is measured in the Red(FL-2)channel on most

flow cjdometers. JC-1 does not accumulate in mitochondria with depolarized Av|/ due to

apoptosis and remains in the cjdoplasm as monomers. JC-1 that fluoresces in the FL-1 is
indicative of depolarized A\\i. The JC-1 assay will measure the red/green fluorescence in

a quantitative approach using the fluorescence-activated cell sorter(FACS). MCF-7 cells

will be cultured to an optimal density of 1.0x10^ in 25T flasks and treated with RSV (10
M). Cells will be detached and centrifuged at 800 g for 5 minutes at room temperature.

Freshly prepared JC-1 Working Solution (0.5 ml) was added to each pellet, followed by
incubation 15 min at 37°C in a CO2 incubator. Cells will be resusupended in Ix Assay

Buffer and analyzed immediately by flow c5d:ometry using the Cellquest program (Becton
Dickinson).

Statistical analysis

Values are expressed as the mean ± SEM. Statistical differences between mean
values were determined by one-way ANOVA,SPSS 11.0 software(SPSS,INC.,
Chicago, IL). A level ofP < 0.05 was considered significant.
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CHAPTER FOUR
RESULTS

Resveratrol effect on cell growth and survival

To assess cell proliferation, MCF-7 cells were treated with RSV and examined by

BrdU incorporation. Fig. 2A shows that BrdU incorporation by MCF-7 cells treated with

10"^ M RSV was significant when compared with control(p<0.01) and RSV 10"^
(p<0.05)treated groups at 24 and 48 hrs. Since IGF-II exerts its effects by binding mainly

to the IGF-IR, we blocked the IGF-IR on cells treated with 10"® M RSV. Our results show
that IGF-IR antibody significantly decreased BrdU incorporation in MCF-7 cells treated

with RSV 10"® M (p<0.05).
Increasing concentrations of proIGF-II(10-100 ng/ml) were added to MCF-7 cells

treated with RSV (10"^ M)to determine if proIGF-II could prevent cell death. Figure 2B
shows that addition of pro-IGF-II at 24 and 48 hrs, significantly prevented cell death even
at the lowest IGF-II concentration used(10 ng/ml). The IGF-II response plateau at 50

ng/ml. This data indicates that proIGF-II is able to rescue MCF-7 cells(p < 0.01)from

the growth inhibitory effect ofRSV (10"^ M).
The MTT cell viability assay was used to determine if RSV effect on IGF-II

modulates cell survival of MCF-7, T47D(ER+)breast cancer cells, Hs578T(ER- breast

cancer cell line) and MCF-lOA (ER-)breast epithelial cells. Figure 3A shows that

treatment of MCF-7 cells with RSV (10"'^M) caused a significant decrease in cell

viability at 24 and 48 hrs. In contrast, treatment with RSV (10"® M)increases cell
survival, but this increase is statistically significant at 48 hrs (lower panel A). Addition of

the IGF-IR antibody blocks the effect of RSV (10"®) at 24 and 48 hrs (fig. 3A).
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To determine whether the observed effects ofRSV on IGF-II are mediated

through the estrogen receptor(ER), MCF-7 cells treated with RSV(10 ^ and 10
M)were co-incubated with or without the estrogen antagonist tamoxifen(TAM). TAM

(10'^ M)completely abolished the increase in cell number induced by RSV (10'^ M)(fig.
3B),24 and 48 hrs post treatment(p<0.001). No significant difference was observed

between the group treated with RSV (10'"^ M)and the group treated with TAM and RSV
(10"')(fig. 3B).
We also assessed the effect ofRSV on IGF-II protein levels and cell growth in the

estrogen receptor positive(ER+)T47D,estrogen receptor negative(ER-)Hs578t and
MCF-IO cells. Figure 4A similar effect on cell growth, as seen on MCF-7 cells, was

observed on T47D cells, were RSV (10"^ M)induced increase in cell number(*p<0.05),

while the opposite effect was seen with RSV (10""^ M)(**p<0.01).
Figure 5 shows that RSV 10"^ M had no effect on the MCF-10(panel A)and Hs578t
(panel B)cell lines, 24 and 48 hrs post-treatment. Although HS578t and MCF-10 cells do

not express ERa,treatment with RSV (10"^ M)caused cell growth inhibition of both cell
lines, as assessed by the MTT assay. Addition of proIGF-II(10-100 ng/ml)to RSV (10
M)treated MCF-IO cells, blocked RSV growth inhibitory effect(Fig. 10).

Effect ofresveratrol on IGF-IIprotein secretion

Next,I screened the effect of different RSV concentrations (10'^ -10""^ M)on IGFII protein secretion in MCF-7 cells. As seen in figure 6 the only changes in IGF-II protein

were detected with RSV treatment of 10""^ and 10"® M,thus we expanded our experiments

using only RSV 10""^ and 10"® M for further characterization. Figure 7A shows a Western
blot ofIGF-II secreted at 24 and 48 hr after RSV treatment at 10""^ and 10"® M. Our results
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show a differential effect on IGF-II secretion that is RSV concentration dependent.

Treatment with 10'^ M RSV induced a two-fold increase in proIGF-II secretion(17kDa)

while higher RSV concentration (lO""^ M)induced 30% decrease in IGF-II secretion.

Figure 8 shows that RSV(lO'^M)inhibits IGF-II and RSV (10 ^ M)stimulates IGF-II in
T47D breast cancer cells at 24 and 48 hrs. Figure 7A (lower panel)show bar graph

representations of densitometric analysis ofIGF-II densitometry units (integrated density
units,IDV)normalized to P-actin protein units on three separate experiments. As seen,

treatment with RSV (lO'^^M) significantly (*p<0.05)inhibited IGF-II, while RSV (10 ®
M)significantly increased IGF-II protein levels(**p<0.01). Please note that although
only one western blot is depicted as a representative experiment, the bar graphs represent
3 separate experiments done in triplicate(3 western blots per experiment).
Since estradiol regulates both,IGF-I and IGF-II mRNA (both genes have the ER

consensus sequence), we measured IGF-I protein secretion into the media of MCF-7 cells
to determine if RSV also regulated IGF-I. No IGF-I(proIGF-I or mature) was detected in
media from control or RSV treated cells at any studied concentration (Fig.7B). Thus,

even though IGF-I and IGF-II are regulated by estradiol, RSV regulates only IGF-II.

Modulation ofIGF-II mRNA by resveratrol

The concentration-dependent effect of RSV on IGF-II gene expression was

assessed by Northern blot analysis following 12(fig. 9A)and 24(fig 9B)hrs treatment.
Since IGF-II protein levels changed at 24 and 48 hrs, we reasoned that mRNA changes
may occur earlier and chose to analyze mRNA levels at 12 and 24 hrs post-treatment.

Figure 9(A,B)shows increased IGF-II mRNA,when cells were treated with 10"^ M
RSV.In contrast, a decrease in IGF-II mRNA was observed when cells were treated with
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lO'"^ M RSV. Figure 9(lower panels A and B)show bar graph of densitometric analysis
ofIGF-II densitometry units (integrated density units,IDV)normalized to Cyclophilin
mRNA densitometry units on three separate experiments. Please note that only one
northern blot is shown for representation purposes, while data from 3 separate

membranes of3 different experiments was used in the bar graphs below for the statistical

analysis. The increase in IGF-II mRNA when cells were treated with RSV (10"^ M)and
compared to control was 3 fold at 12 hrs(p<0.01)and 2.5 fold at 24 hrs(p<0.01). In
contrast, IGF-II mRNA decreased 3 fold (p<0.05) at 12 hrs and 2 fold (p<0.05) at 24 hrs

when cells were treated with 10'"^ M RSV. The most significant differences(p<0.001)
were seen between the IGF-II mRNA of cells treated with RSV 10"^ as compared to cells
treated with RSV lO"'^; six fold difference at 12 hrs and 4.5 fold at 24 hrs.
No changes in IGF-II expression were observed in the ER- MCF-10(figure 10)

and Hs578t(figure 16)cell lines after RSV treatment(10'^ M or 10'"^ M)

RSV effect on Cathepsin D secretion

We also examined CD secretion by MCF-7 cells treated with varying

concentrations ofRSV (10"^-10"'* M). Our results indicate that RSV exerts a concentration
dependent effect on CD secretion 24 and 48 hrs post-treatment, as shown in Fig; 12A.

RSV (10"^) increases while RSV(IC*)decreases CD secretion. Thus, we concentrated

our study on RSV treatment at 10"^ and 10"^ M. Figure 12B (upper panel)shows
representative Western blots(of 3 independent experiments). As seen on this figure, RSV

(10"^ M)increased CD secretion (p<0.01) while RSV (10"^ M)inhibited CD secretion
(p<0.01). Please note that only one western blot is shovm for representation purpose only.
Figure 12(lower panel B)shows a bar graph representation of densitometric analysis of
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CD densitometry units (integrated density units,IDV)normalized to P-actin densitometry

units ofthree separate experiments. As seen, RSV induced significant(p< 0.01)changes

in CD secretion when cells were treated at 10'^ and 10"^ M.CD changes correlated with
IGF-II levels as observed in figure 12C.

Similarly, figure 13A (upper panels)shows RSV effect on CD secretion in T47D

breast cancer cell after 24 and 48 hrs of treatment. RSV (10'^ M)induced an increase in

CD secretion(p<0.01) while RSV (10"'* M)inhibited CD secretion (p<0.01). Figure 13A
(lower panels)show bar graph representation of densitometric analysis of CD normalized
to P-actin densitometry units ofthree separate experiments. Likewise, as seen in MCF-7
cells treated with RSV CD changes correlated with IGF-II levels (figure 13B).

RSV ejfect on Cathepsin D mRNA levels

The effect ofRSV on CD gene expression in MCF-7 cells was assessed by
Northern blot analysis. Figure 14A shows a representative northern blot(of3 separate

experiments) of CD at 12 and 24 hrs after RSV treatment. Since CD protein levels
changed at 24 and 48 hrs, we reasoned that mRNA changes may occur earlier and chose
to analyze mRNA levels at 12 and 24 hrs post-treatment. The decrease observed in CD

mRNA when cells were treated with RSV (10"'* M)is significant at 12(p<0.05) and 24
hrs(p<0.01). In contrast, there were no changes in CD mRNA when cells were treated

with RSV (10"^ M). Figure 14A (lower panel)shows bar graph representations of
densitometric analysis of CD densitometry units (integrated density units,IDV)
normalized to eyelophilin mRNA densitometry units on three separate experiments.

Please note that only one northern blot is shown for representation purposes, while data
from 3 separate membranes of 3 different experiments were used in the bar graph below
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for the statistical analysis. Figure 14B shows that RSV treatment at high concentration

(10"%)inhibited IGF-II mRNA at 12 and 24 hrs, while RSV (10"^ M)increased IGF-II
mRNA. Furthermore, since the increase in CD secretion seen when cells are treated with

RSV (10"^ M)does not correlate with increased CD mRNA levels, we conclude that
treatment with RSV (10"^ M)modulated CD secretion by increasing the levels ofIGF-II.

Transfection withproIGF-IIsense cDNA induces increased CD secretion in Hs578t and
MCF-lOA cells

We also addressed the question of whether IGF-II modulates CD routing and
secretion on hormone-independent ERa(-)breast cancer(Hs578t) and epithelial(MCF-

lOA)cells. We transfected Hs578t and MCF-lOA cells with proIGF-II sense cDNA and
measured CD protein secretion and mRNA levels after 48 hrs. Figure 15A shows IGF-II
and CD Western blots from IGF-II transfected cells(Clones IIB8,IIB9 and IIBl 1)or

vector only(CMV)transfected Hs578t cells compared to non-transfected cells. As clearly
seen, all transfected clones secreted high amounts of pro-IGF-II that correlated with

increased CD secretion(15A). IGF-II was undetectable in control cells, although reactive
CD bands were observed. Figure 14B shows corresponding Northern blots. Although
three different IGF-II transcripts are seen (4.8, 2.2, and 0.7 kb), the major form

transcribed by Hs578t cells corresponds to the 2.2 kb transcript. No significant change in
CD mRNA is seen. Cyclophilin was used as a loading control. Similarly, figures 15C and
D show MCF-lOA cells Western and Northern blot analyses of proIGF-II and CD from

transfected (clones IIC5,IID5 and IIF4) and control cells(CMV). As observed in figure

15D, all IGF-II transcripts (4.8, 2.2, and 0.7) increase in transfected MCF-lOA cells. The
2.2 kb transcript represents mRNA from promoter 2 and the 0.7 kb is the transfected IGF58

II cDNA.Interestingly, CD mRNA also increased significantly in transfected MCF-lOA
cells when compared to control cells. Cyclophilin was used as a loading control.

Resveratrol effect on IGF-IIand CD secretion in ER(-) human breast cancer and
epithelial cells

Since RSV exerts both ER-dependent and ER-independent effects on human

breast cell lines and RSV (10'"^) regulated CD gene expression in ER(+)breast cancer
cells, we also studied IGF-II and CD secretion in Hs578t breast cancer and MCF-lOA

breast epithelial cell lines after RSV treatment(10'^ and 10""^ M). For this purpose, we
measured IGF-II and CD protein secretion in RSV treated ERa(-)Hs578t breast cancer

and MCF-lOA breast epithelial cells. Figure 16 (right panel) shows a representative

Western blot(of3 separate experiments) ofIGF-II and CD secreted from Hs578t cells, at
24 and 48 hrs. As seen, control or RSV treated Hs578t cells did not secrete IGF-II

(mIGF-II/proIGF-II) and no changes in CD secretion were observed after RSV treatment.

Figure 16 (left panel)shows that MCF-lOA cells secrete IGF-II, but RSV treatment does
not change IGF-II or CD secretion from MCF-lOA cells after 24 and 48 hrs.

Effect ofRSV and IGF-IIon Bcl-2 and survivin protein levels

We also studied the effect of RSV (lO""^ M)on Bcl-2 and survivin protein levels. As

seen on figure 17(upper panel), RSV (10"^) induced a significant decrease (p<0.05)in
Bcl-2 protein levels 3 hrs post-treatment. Co-treatment with the mature or the precursor

form ofIGF-II(100 ng/ml) blocked RSV (lO'"^) inhibitory effect. Furthermore, as seen on

figure 17, addition of proIGF-II(but not mIGF-II)to RSV (10"'*) treated cells induced a
significant increase (p<0.05)in Bcl-2 protein levels as compared to control group 6 hrs
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post-treatment. Figure 18 shows a significant decrease (p<0.05)in survivin levels after

RSV (10""^) treatment. Addition ofIGF-II(mIGF-II or proIGF-II) did not block RSV
inhibitory effect on survivin levels 3 hrs post-treatment. Noteworthy, addition of proIGFII, but not mIGF-II, induced an increase in survivin levels 6 hrs post-treatment as

compared to RSV (10'"^) treated group. Figures 17-18(lower panels)show bar graph
representations of densitometric analysis of Bcl-2 and survivin densitometry units
(Integrated Density Units,IDV)normalized to P-actin densitometry units on 3 separate
experiments. Please note that although only one western blot is depicted as a

representative experiment, the bar graph represents three separate experiments done in
triplicate (three western blots per experiment).

Effect ofRSV onBcl-2 and survivin protein levels in proIGF-II transfected MCF-7 cells
To further confirm the stimulatory effect of proIGF-II on Bcl-2 and survivin, we
transfected MCF-7 cells with proIGF-II sense cDNA and measured Bcl-2 and survivin

protein levels by Western blot, 3 and 6 hrs after RSV (10"'^ M)treatment. As seen on
figure 19 transfection with IGF-II sense cDNA blocked RSV (10""^ M)inhibitory effect on
Bcl-2(panel A)and survivin (panel B)as early as 3 hrs post-treatment.

RSV and IGF-II effects on Bcl-2 and survivin mRNA levels

RSV (10""^ M)and IGF-II effects on Bcl-2 and survivin gene expression were
assessed by Real Time-PCR following 6 hrs co-treatment. To evaluate the effect of

mature and precursor IGF-II(mIGF-II and proIGF-II) on Bcl-2 and survivin gene

expression in RSV (10""^ M)treated cells, MCF-7 cells were also incubated in the
presence of 100 ng/ml of either mIGF-II or proIGF-II. As seen on figure 20, addition of
60

proIGF-II to RSV treated cells induced a two fold increase in survivin mRNA levels, but
not in Bcl-2 mRNA. On the contrary, mlGF-II did not induce any significant changes in
survivin gene expression, although a decrease in Bcl-2 levels is seen.

Effect ofRSV and IGF-II(mIGF-II and proIGF-II) on Caspase -7 activation

Caspase 7 enzymatic activity was measured by a caspase activation assay. Figure
21 shows an increase in relative fluorescence units(RFU)induced by proteoljdically
released fluorochrome from the DEVD-AMC substrate, 3(panel A)and 6(panel B)hrs

after RSV (10""^) treatment. On the contrary, a decrease in caspase activation was
observed when cells were co-treated with IGF-II(100 ng/ml). Of note, proIGF-II induced

a statistically significant decrease (p<0.01)in caspase activity, while mIGF-II did not
(p>0.05).

RSV and IGF-II effects on mitochondrial membrane potential

In order to elucidate RSV (lO'"^) and IGF-II effects on mitochondrial membrane
depolarization as an indicator of apoptosis, the JC-1 assay was performed. The JC-1 dye
does not accumulate in mitochondria with depolarized Av|/ due to apoptosis and remains
in the cytoplasm as monomers. These monomers have lowered fluorescence in the FL-2
channel. As seen in figure 22, a significant increase in FL-1 channel fluorescence occurs

with RSV (10""^) treatment 9 hrs post-treatment when compared to control and proIGF-II
treated cells. Of note, mIGF-II was not able to protect the cells as significantly as

proIGF-II, as shown by a greater increase in the FL-1 channel fluorescence indicative of
mitochondrial membrane depolarization.
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RSVeffect on cell survival ofIGF-II transfected MCF-7 cells
To assess cell survival, IGF-II(mIGF-II or proIGF-II) transfected MCF-7 cells

were treated with RSV (10"'' M)and examined by the MTT assay after 3 and 6 hrs of
treatment. Figure 23 shows a significant decrease in cell number in RSV treated cells
when compared to control after 3(p<0.01)and 6(p<0.001)hrs treatment. A significant
increase in cell survival(p<0.01) was seen in MCF-7 cells transfected with proIGF-II
than in cells transfected with mIGF-II(p<0.05) after 6 hrs treatment when compared to
control. Noteworthy, RSV treatment induced a more significant decrease in MCF-7
transfected with mIGF-II(p<0.01)than in proIGF-II transfected cells (p<0.05).
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Figure 21. RSV effect on caspase -7 activation. Panels A and B show caspase 7

activation assay data represented as relative fluorescence units (RFU), 3 and 6 hrs after
RSV and mature or precursor IGF-II (100 ng/ml) treatment. Asterisks indicate values
significantly different from control (*<p0.05, **p<0.01).
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CHAPTER FIVE

DISCUSSION

[

Breast Cancer

Cancer is a major public health problem in the United States and other developed
countries. Breast cancer represents the most common cancer among women in the US.
212,930 new cases have been estimated for 2005. California has the highest number of

cases per state (21,170). Although the carcinogenic process may be driven by mutation,
there are clearly many epigenetic variables, particularly those relating to the action of
autocrine, paracrine and endocrine regulatory molecules, which include the IGFs, that
constitute important determinants during the latent period before invasion and metastasis
occur. Pharmacologic modulation ofthese regulatory pathways, through the effective use

of drugs and nutrients, offers great potential for the treatment of cancer(Spom and Suh,
2000).

Resveratrol-induces IGF-II expression in ER+ Breast Cancer Cells

Resveratrol(RSY)is a promising and novel diet-derived cancer chemotherapeutic

agent. RSY is a phytoalexin generated in response to environmental stress or pathogenic
attack in grapes, mulberries, peanuts and plants ofthe Cassia quinquangulata family

(Goldberg et al, 1996). RSY,a relatively new member of a class of chemopreventive

agents like retinoids and other diet-derived compounds, has been shown to retard or
1

prevent steps of carcinogenesis and mediate differential responses in various tissues,

organs and in vitro models. RSY inhibits the growth of cancer cells of different origins
(Sciacca et al 1999, 2000; Denley et al 2004; Scott and Firth 2004). However,the effect
ofRSY on breast cancer cell growth and ER-mediated gene activation is a controversial
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subject under intense investigation. Several studies reported that treatment with RSV
stimulated cell proliferation ofthe ER-positive, T47D and MCF-7 breast cancer cell lines,
(Gehm et al 1997; Nakagawa et a/2001). In contrast, other reports have shown that RSV
treatment inhibited cell growth of both ER-positive and ER-negative breast cancer cells
(Lu and Serrero 1999; Hsieh et al 1999; Damianaki et al 2000; Mgbonyebi et al 1998).
Molecules involved in RSV biphasic response, and risks associated with RSV

usage remain mostly unknown. Our study demonstrated that RSV regulates IGF-II gene

expression in a dose-dependent manner in MCF-7 and T47D breast cancer cell lines. At

low concentrations (10'® M),RSV stimulated IGF-II gene expression leading to an
increase in proIGF-II secretion. Furthermore, the increase in proIGF-II levels correlated
with an increase in MCF-7 and T47D cell growth, suggesting that IGF-II mediated RSV

stimulatory effects, potentially increasing the risk of breast cancer growth.
Our previous studies have shown that both MCF-7 and T47D cells are very

sensitive to IGF-II, they express IGF-I receptors and that IGF-II actions are mediated

through the IGF-I receptor(DeLeon et al 1988, 1992). Since the IGF-IR antibody

blocked the stimulatory effect of RSV treatment(10'® M)in this study, we conclude that
the IGF-II effect is mediated, primarily, through the IGF-IR. In addition, the blocking
effect ofthe antibody on both, the MTT(used to estimate cell number and viability) and

the BrdU assays(DNA sjmthesis) also demonstrated that IGF-II regulates both cell
survival and growth.

Even though our study demonstrated that RSV does not regulate IGF-II in the ER

negative MCF-lOA breast epithelial cell line, exogenously added pro-IGF-II was able to

rescue these cells as well as the ER(-i-) breast cancer cells from RSV (10''* M)induced
growth inhibition and cell death. These results demonstrate that all cell lines studied are
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responsive to IGF-II, but only ER+ cells are stimulated by RSV (10'^ M). Thus, RSV
stimulatory effect requires the ER while the inhibitory effect ofRSV is ER independent.
RSV inhibits the binding ofE2 to the ER and induces ER-dependent

transcriptional activation of genes with an estrogen-response element(ERE). This effect
can be inhibited by specific estrogen antagonists(Gehm et al 1997). TAM,an estrogen

antagonist, suppresses transcriptional activity by blocking E2 co-activator binding and
promoting co-repressor recruitment(Yamamoto et al 2001). Our data demonstrated that

TAM inhibits RSV (10"^)induced cell growth, thus confirming that the ER is required in
mediating RSV stimulatory effect on IGF-II levels.
Of note, RSV did not stimulate IGF-I. Both,IGF-I and IGF-II are regulated by E2

because both genes have the ERE(Yee and Lee, 2000). Since our study showed that RSV
regulated IGF-II, not IGF-I, RSV regulation ofIGF-II is might be distinct from E2
regulation ofthese peptides.

Many reports from other laboratories have shown a biphasic effect of estrogen or

RSV on many different systems, as we have observed with RSV in our study. Amara and
Dannies(1983)reported that estradiol stimulated GH cell growth at low concentration but
significantly inhibited growth at higher concentrations. Likewise, Kuwajerwala et al
(Kuwajerwala et al, 2002) demonstrated that RSV exerted opposing effects on cell cycle
progression in prostate cancer cells. RSV induced the cell cycle S phase at low
concentrations but it inhibited DNA synthesis at high concentrations.

The specific signaling pathways activated by RSV are largely unknown. Since
this estrogen antagonist binds the ER it will induce genomic effects through the ER

pathway as seen with proIGF-II regulation in our study. Other reports have also shown
that RSV can stimulate non-genomic effects by binding to the estrogen membrane
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receptor(Pozo-Guisado et al, 2004). The changes in IGF-II induced by RSV in ER(+)
cells will affect gene targets in the IGF-I receptor pathway as well as genes in the insulin
receptor(isoform A)pathway. To our knowledge, there is no published data showing
RSV stimulation ofIGF-II or its downstream targets.

Our study shows that RSV effects on cell growth are mediated by proIGF-II.

Furthermore, proIGF-II effects are mediated through the IGF-IR. In addition, since RSV

regulates proIGF-II in ER(+)(not ER-)breast cancer cells and this effect is blocked by
TAM,we conclude that RSV regulation ofIGF-II is mediated through the ER. In

contrast, the inhibitory effect ofRSV is independent ofthe ER presence since RSV (10
M)inhibited proliferation and cell survival ofER(-) cells.

IGF-II overexpression leads to Cathepsin D secretion in Breast Cancer Cells

The lysosomal enzyme eathepsin-D(CD)and insulin-like growth faetor-II(IGFII), which shares a common IGF-II/mannose-6-phosphate(M6P)transmembrane

receptor, are both synthesized and secreted by breast cancer cells, upon which they might
exert an intracrine/autocrine control on proliferation.

Cathepsin D(CD)is a prognostic indicator of metastasis and survival for breast

cancer patients (Rochefort et al, 2000), making this protease an important target for
chemotherapeutic agents. Because both proteins, IGF-II and CD bind to the IGF-

II/M6PR, binding of one ligand interferes with the binding ofthe other ligand (Faridi et
al, 2004).

Treatment with RSV (10"^ M)caused an increase in CD secretion in MCF-7 and
T47D cells without a corresponding increase in CD mRNA. Increased IGF-II secretion
was associated with an increase in IGF-II mRNA levels. Although CD is regulated by E2,
our results indicate that RSV-induced increase in CD secretion does not correlate with
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CD mRNA changes. In the eontext of CD gene aetivation, it is known that ERa
interaction with USF-1 and USF-2 in the CD promoter is a critical step in hormone

aetivation ofCD gene transcription, a step that might not take place when RSV (lO^M)
binds the ERa.

Thus, changes in CD secretion are related to the derouting ofintraeellular CD
caused by IGF-II expression. Since normal mammary cells do not express IGF-II, no
secretion of CD should oecur. Nevertheless, MCF-lOA eells express the 4.8 and 2.2 IGF-

II mRNAs.Increased IGF-II expression in these "normal" mammary eells further
increases secretion and higher expression of CD mRNA levels. This finding is of great

significance, beeause in addition to indueing degradation ofthe extracellular matrix
(ECM),CD also eauses proteolysis ofIGF binding proteins(IGFBPs)leading to
increased IGF bioavailability and stimulated cell growth(Conover and DeLeon, 1993;
Clausen et al, 1997). Secreted pCD is involved in eancer eell growth and/or
differentiation. Since MCF-lOA cells were derived from tissue with fibrocystie changes,

we propose that they represent the earlier steps in the development of breast cancer. By

promoting CD secretion IGF-II expression alters the cell mieroenvironment increasing
cell proliferation. Thus, both IGF-II and CD may be associated with the increased risk of
breast cancer observed in women with fibrocystie disease. On the contrary, treatment

with RSV (10"^ M)had an inhibitory effeet on CD gene expression and protein secretion
in ER(+)MCF-7 and T47D cells.

RSV has also been shown to exert ER-independent effects on both, cells

expressing the ER and cells that do not express the ER-a. Reeently, RSV has been shown
to activate adenylyl cyelase(AC)/kinase-A pathway in ER(+) MCF-7 as well as in ER(-)
MDA-MB-231 breast eancer eell lines(El-Mowafy and Alkhalaf, 2003). This data
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indicates that recruitment of AC by RSV is not confined to ER(+)MCF-7 cells,thus RSV
effect on AC is independent of the cell ER status. Our study also showed that RSV effect

on CD secretion is only present in ERa(+)human breast caneer cells and not in ERa(-)
cells. Of note, the 52 and 30 kDa CD forms were present in the conditioned media from

MCF-lOA cells, suggesting that a sufficiently acidie pH, whieh is required for CD

processing and activation and is normally found in the microenvironment of malignant
cells, might also be found in the MCF-lOA microenvironment, a significant finding in
terms of potential malignant transformation.

CD is not only associated with cancer progression, but appears to he a rate

limiting faetor in stimulating in vitro and in vivo tumor growth; CD stimulates directly or
indirectly both, cancer cell proliferation and tumor angiogenesis independently of its
proteolytie aetivity and may provide some protection against tumor apoptosis(Berchem
et al, 2002).

IGF-IIRegulates Genes Involved in the Apoptotic Pathway

RSV has been shown to inhibit cell survival and induee apoptosis of cancer cells

of different origin by mechanisms including: a caspase-independent pathway with

downregulation of NF-kappaB (Pozo-Guisado et al, 2005), serine phosphorylation and
acetylation of p53 tumor suppressor protein(Zhang et al, 2004), sensitization for TRAIL-

induced apoptosis(Fulda and Debatin, 2004), or through activation of CD95 signalingdependent apoptosis(Clement et al, 1998).

Bcl-2 and survivin represent important proteins involved in the control ofthe

mitoehondrial apoptotie process. Bcl-2 and several pro-survival proteins associate with
the mitoehondrial outer membrane and the endoplasmic retieulum/nuclear membrane and
maintain their integrity. Bcl-2 can prevent cytochrome c release and hence caspase
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activation(Cory and Adams,2002). Survivin, a member ofthe inhibitor of apoptosis

protein family, has been implicated in protection from apoptosis and regulation of
mitosis. Survivin kinetics differ from that of Bcl-2 in that more than 70 % ofthe protein

is discharged from the mitochondria into the c)d:osol within 4 hrs of apoptotic stimulation,

suggesting that loss of mitochondrial membrane integrity results in the release not only of
cell death amplifiers but also a cell death antagonist, i.e., survivin(Dohi et al, 2004).
Our study shows that IGF-II mediates RSV effect on cell survival and apoptosis
by regulating the anti-apoptotic proteins Bcl-2 and survivin. Of note proIGF-II had a

more significant effect on Bcl-2 and survivin protein levels than mIGF-II. Similarly
MCF-7 cells transfected with proIGF-II cDNA were protected from RSV-induced
apoptosis, while mIGF-II transfected cells were less protected.

Reports from other laboratories have shown that IGF-I induces promoter activity
of the Bcl-2 gene via a signaling pathway mediated by MAPK kinase 6/p38p

(Pugazhenthi et al, 1999), interestingly we previously showed that RSV only stimulates
IGF-II, not IGF-I, in breast cancer cells and our present study shows that proIGF-II does

not increase Bcl-2 gene expression, but it does increase Bcl-2 protein levels possibly by

affecting its translation rate. This difference between IGF-I and IGF-II effect on Bcl-2
expression is of great significance, due to the fact that both growth factors bind and
activate the same receptor, but their downstream effects are not necessarily the same.
Unique among other inhibitor of apoptosis proteins (lAPs), survivin, like IGF-II,

is selectively expressed during development and in many human cancers, but not in
normal adult tissues, indicating that its overexpression in cancers plays a role in apoptosis

inhibition and tumor progression. RSV has been shown to downregulate survivin in
leukemia cell lines (33), but no pathway has been delineated yet. In the present study, we
91

showed that RSV (10"'^) inhibits survivin gene expression through IGF-II downregulation
in MCF-7 hreast cancer cells. Addition ofrecomhinant human proIGF-II(not mIGF-II)

blocked RSV inhibitory effect on survivin gene expression and protein levels in MCF-7
cells. Similarly, Transfection with mIGF-II or proIGF-II cDNA,protected from RSV-

induced apoptosis, although a more significant effect on cell survival was seen in proIGFII transfected cells than in mIGF-II transfected cells. To our knowledge,this is the first

study that shows not only a differential effect induced by the two IGF-II forms on breast
cancer cell survival, hut also identifies IGF-II as a key molecule involved in RSV effects
on the anti-apoptotic proteins Bcl-2 and survivin.

The differential effect of proIGF-II and mIGF-II in regulating anti-apoptotic proteins and

preventing mitochondrial depolarization represents a novel mechanism by which proIGFII promotes cancer progression.

Thus, we propose that RSV could increase the risk of breast cancer growth at low
concentration by increasing proIGF-II levels, and that proIGF-II is a key player in the
mechanism of action ofRSV and a promising target to develop new therapies for breast
cancer treatment and chemoprevention.

92

REFERENCES

Adamo ML, Neuenschwander S, LeRoith D, Roberts Jr CT. 1992 Structure, expression,
and regulation ofthe IGF-I gene. Adv Exp Med Biol 343: 1-11

Ahmad N,Adhami VN,Afaq F, Feyes DK,Mukhtar H. 2001 ReSveratrol causes wafl/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human
epidermoid carcinoma A431 cells. Clin Cancer Res 7: 1466-1473

Allander SV, Bajalica S, Larsson C,Luthman H,Powell DR, Stem I, Weber G,Zazzi H,
Ehrenborg E. 1993 Structure and chromosomal localization of human insulin-like
growth factor binding protein genes. Growth Regul 3:3-5

Altieri D.(2003) Validating survivin as a cancer therapeutic target. Nature Reviews 3:4654

Altieri D.(2003) Survivin in apoptosis control and cell cycle regulation in cancer.
Progress in Cell Cycle Research 5: 447-452
Amara J F., Dannies P S. 1983 17 beta-Estradiol has a biphasic effect on GH cell growth.
Endocrinology. 112(3): 1141-3

An J, Tzagarakis-Foster C, Scharchmidt TC, Lomri N, Leitman DC. 2001 Estrogen
receptor p-selective transcriptional activity and reemitment of coregulators by
phytoestrogens. J Biol Chem 276: 17808-17814

Andress DL, Bimbaum RS. (1991) A novel human insulin-like growth factor binding
protein secreted by osteoblast-like cells. Biochem Biophys Res Commun 176:
213-218

Augereau P, Garcia M,Mattei MG,Cavailles V,Depadova f, Derocq D.(1988) Cloning
and sequencing ofthe 52K cathepsin D cDNA of MCF-7 breast cancer cells and
mapping on chromosome 11. Mol Endo 2: 186-192
Aziz M.H., Kumar R., Ahmad N.(2003)Cancer chemoprevention by resveratrokin vitro
and in vivo studies and the underlying mechanisms. Int J Oncol 23(1): 17-28

Bach A, Hsieh S, Sakono K,Fujiwara H,Perdue J, Reehler M.(1993)Binding of mutants
of human IGF-II to insulin-like growth factor binding proteins 1 to 6. J Biol Chem
268: 9246-9254

Basly JP, Marre-Fumier F,Le Bail JC, Habrioux G,Chulia AJ 2000
Estrogenie/antiestrogenic and scavenging properties of(E)- and (Z)- resveratrol.
Life Sei 66:769-77

Bates P,Fisher R, Ward A,Richardson L, Hill DJ, Graham CF.(1995) Mammary cancer

in transgenic mice expressing insulin-like growth factor II. British Joumal of
Cancer 72: 1189-1193
93

Baxter RC,Saunders H.(1992)Radioimmunoassay ofinsulin-like growth factor binding
protein 6 in human serum and other body fluids. J Endocrinol 134: 133-139
Berchem G., Glondu M., Gleizes M.,Brouillet J.P., Vignon F., Garcia M., Liaudet-

Coopman E.(2002)Cathepsin D affects multiple tumor progression steps in vivo:
proliferation, angiogenesis and apoptosis. Oncogene 21: 5951-5955
Bemardini S, Cianfarani S, Spagnoli A, Anniechiarico-Petruzzelli M, Melino G,
Massoud R, Boscherini B, Finazzi-Agro A, Rosenfeld RG, Federici G. 1994
Expression and down-regulation by retinoic acid of IGF binding protein-2 and —4
in medium from human neuroblastoma cells. J Neuroendocrinol. 6: 409-413

Bemhard D,Tinhofer I, Tonko M,Hubl H, Ausserlechner MJ, Greil R,Kofler R, Csordas
A 2000 Resveratrol causes arrest in the S-phase prior to Fas-independent
apoptosis in CEM-C7H2 acute leukemia cells. Cell Death and Differ 7: 834-42
Bhat KP,Pezzuto JM 2002 cancer chemopreventive activity of resveratrol. Ann N Y
AcadSci 957:210-29

Blahovec J, Kostecka Z,Lacroix M-C, Cabanie L, Godeau F, Mester J, Cavailles F.

(2001) Mitogenic activity of high molecular weight forms ofIGF-II in amniotic
fluid. J of Endocrinol 169: 563-572

Bautista CM,Baylink DJ, Mohan S.(1991)Isolation of a novel insulin-like growth factor
binding protein from human bone: a potential candidate for fixing IGF-II in
human bone. Biochem Biophys Res Commun 176: 756-763

Baxter RC. 1997 Molecular aspects of insulin-like growth factor binding proteins. Adv
Mol Cell Endocrinol. 1: 123-159

Bowers JL, Tyulmenkov VV,Jemigan SC,Klinge CM.(2000) Resveratrol acts as a
mixed agonist/antagonist for estrogen receptors a and p. Endocrinology 141(10):
3657-3667

Bowers JL, Tyulmenkov VY,Jemigan SC, Klinge CM.2000 Resveratrol acts as a mixed
agonist/antagonist for estrogen receptors a and p. Endocrinology 141: 3657-3667
Braulke T.(1999)Type-2 IGF receptor: a multiligand binding protein. Horm Metab Res
31:242-246

Brissenden JE, Ullrich A, Francke U. 1984 Human chromosomal mapping of genes for
insulin-like growth factors I and II and epidermal growth factor. Nature 310: 781784

Brouillet JP, Dufour F, Lemamy G, Garcia M, Schlup N, Grenier J, Mani JC, Rochefort
H 1997 Increased Cathepsin D level in the serum of patients with metastatic
94

breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer
79; 2132-2136

Buckbinder L, Talbott R,Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR,Kley N.
(1995)Induction ofthe growth inhibitor IGF-binding protein 3 by p53. Nature
377: 646-649

Byrd JC, Devi GR,de Souza AT,Jirtle RL, MacDonald RG.(1999)Disruption ofligand
binding to the insulin-like growth factor Il/mannose 6-phosphate receptor by
cancer-associated missense mutations. J Biol Chem 274(34): 24408-24416

Camacho-Hubner C, Busby WH Jr, McCusker RH, Wright G, Clemmons DR.(1992)
Identification of the forms of insulin-like growth factor binding proteins produced
by human fibroblasts and the mechanisms that regulate their secretion. J Biol
Chem 267: 11949-11956

Carbo N, Costelli P, Baccino MF. 1999 Resveratrol, a natural product present in wine,
decreases tumor growth in a rat tumor model. Biochem Biophys Res Commun 54:
739-743

Cavailles V., Augereau P., Rochefort H.(1993)Cathepsin D gene is controlled by a
mixed promoter, and estrogens stimulate only TATA-dependent transcription in
breast cancer cells. Proc Natl Acad Sci 90: 203-207

Clausen M,Berugisser D,Schuller AG,Matzner U,Braulke T.(1995)Regulation of
insulin-like growth factor binding protein 6 and mannose-6-phosphate/IGF-II
receptor expression in IGF-IL-overexpressing NIH-3T3 cells. Mol Endocrinol 9:
902-912

Claussen M., Kubler B., Wendland M., Neifer C., Schmidt B., Zapf J., Braulke T.(1997)
Proteolysis of insulin-like growth factors(IGF)and IGF binding proteins by
cathepsin D. Endocrinology 138: 3797-3803

Clement M-V,Hirpara JL, Chawdhury S-H,Pervaiz S 1998 Chemopreventive agent
resveratrol, a natural product derived from grapes, triggers CD95 signaling
dependent apoptosis in human tumor cells. Blood 92: 996-1002

Clemmons DR, Camacho-Hubner C, Coronado E, Osbome CK. 1990 Insulin-like growth
factor binding proteins secretion by breast carcinoma cell lines: correlation with
estrogen receptor status. Endocrinology 127(6): 2679-2683
Cohen P, Noveral JP, Bhala A, Nimn SE, Herrick DJ, Grunstein MM. 1995 Leukotriene
D4 facilitates airway smooth muscle cell proliferation via modulation of the IGF
axis. Am J Physiol. 269: L151-L157

Cohen P, Rosenfeld RG.(1995)The IGF axis: in Rosenbloom AL (ed): Human Growth
Hormone. Basic and Scientific Aspects. Boca Raton. CRC Press 43-58
95

Cory S, Adams JM (2002)The Bcl-2 family: regulators ofthe cellular life or death
switch. Nature Reviews 2: 647-656

Costello MC,Baxter RC,Scott CD.(1999) Regulation of soluble IGF-II/M-6-P receptor
in human serum: measurement by enzyme-linked immunoabsorbent assay. J Clin
Endocrinol Metab 84: 611-617

Cullen K.J., Smith H.S., Hill S., Rosen N., Lippman M.E.(1991) Growth factor mRNA
expression by human breast fibroblasts from benign and malignant lesions.
Cancer Res. 51(18): 4978-4985
Couissi D,Dubois V,Remade C, Schonne E, Trouet A.(1997) Western immunoblotting
and enzymatic activity analysis of cathepsin D in human breast cancer cell lines
of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI
182,780. Clin Exp Metastasis 15: 349-360

Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. 1998 Loss of imprinting in
normal tissue of colorectal cancer patients with microsatellite instability. Nat
Med. 4: 1276-1280

Damianaki A,Bakogeorgou E,Kampa M,Notas G,Hatzoglou A,Panagiotou S, Gemetzi
C,Kouroumalis E, Marti PM,Castanas E 2000 Potent inhibitory action ofred
wine polyphenols on human breast cancer cells. J Cell Biochem 78: 429-41

Datta SR,Dudek H,Tao X, Masters S, Fu H,Gotoh Y, Greenberg ME.(1997) Akt
phosphorylation ofBAD couples survival signals to the cell-intrinsic death
machinery. Cell 91(2): 231-241

Daughaday WH, Totwein P. 1989 Insulin like growth factors I and II. Peptide, mRNA
and gene structures, serum and tissue concentrations. Endocr Rev. 10: 68-91
DeChiara TM, Efstratiadis A, Robertson EJ. 1990 A growth deficiency phenolype in
heterozygous mice carrying an insulin-like growth factor II gene disrupted by
targeting. Nature 345: 78-80
De Leon D., Terry C., Asmerom Y., Nissley S.P.(1996)Insulin-like growth factor II
modulates the routing of cathepsin D in MCF-7 breast cancer cells. Endo.
137:1851-1859

De Leon DD, Wilson DM, Bakker B, Lamson G, Rosenfeld RG. 1990 Insulin-like
growth factors binding proteins in human breast cancer cells: relationship to
hIGFBP-2 and hIGFBP-3. J Clin Endocrinol and Metab. 71(2): 530-532
De Leon D. D., Bakker B., Wilson D. M., Hintz R. L., Rosenfeld R. G. 1988

Demonstration of insulin-like growth factor(IGF-I and -II) receptors and binding
protein in human breast cancer cell lines. Biochemical and Biophysical Research
Communications(152): 398-405

96

De Leon D D,Wilson D M,Powers M,Rosenfeld R G. 1992 Effects ofinsulin-like

growth factors(IGFs)and IGF receptor antibodies on the proliferation of human
breast cancer cells. Growth Factors (6): 327-336

De Leon D,Issa N,Nainani S, Asmerom Y.(1999)Reversal of cathepsin D routing
modulation in MCF-7 breast cancer cells expressing antisense insulin-like growth
factor 11. Horm. Metah. Res. 31:142-147

Delmas D,Jannin B, Malki MC,Latruffe N 2000 Inhibitory effect of resveratrol on the
proliferation of human and rat hepatic derived cell lines. Oncol Rep 7: 847-52

Denley A, Wallace JC, Cosgrove LJ, Forbes BE.(2003)The insulin receptor isoform
exon 11-(IR-A)in cancer and other diseases; a review. Horm Metah res 35: 778785

Denley A,Bonython ER,Booker GW,Cosgrove LJ, Forbes BE, Ward CW,Wallace JC
2004 Structural determinants for high affinity binding ofIGF-II to IR-A,the exon
11 minus isoform ofthe insulin receptor. Mol Endocrinol 18(10): 2502-12
Dercks W,Creasy LL. 1989 The significance of phytoalexins in the Plasmopara viticolagrapevine interaction. Physiol Mol Plant Pathol. 34: 189-202

Dingle JT,Poole AR,Lazarus GS,Barret AJ.(1973)Immunoinhibition ofintracellular
protein digestion in macrophages. J Exp Med 137: 1124-1141

Doerr ME,Jones JI.(1996)The roles ofintegrins and extracellular matrix proteins in the
insulin-like growth factor stimulated chemotaxis of human breast cancer cells. J
BiolChem 271:2443-2447

Dohi T, Beltrami E, Wall NR,Plescia J, Altieri DC. (2004) Mitochondrial survivin
inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 114(8): 1117-1127

Dong Z.(2003) Molecular mechanism of the chemopreventive effect ofresveratrol. Mut.
Res. 523-524: 145-150

Dotzlaw H., Leygue E., Watson P., Murphy L.(1996)Expression of estrogen receptor
beta in human breast tumors. Journal of Clinical Endocrinology and Metabolism
82: 2371-2374

Drummond lA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP,Rauscher FJ 3rd.
(1992)Repression ofthe insulin-like growth factor II gene by the Wilms tumor
suppressor WTl. Science 257: 674-678

Dufoumy B, Alblas J, Van Teeffelen HA, Van Schaik FM, Van Der Burg B, Steenhergh
PH, et al. 1997 Mitogenic signaling of insulin-like growth factor-I in MCF-7
human breast cancer cells requires phosphatidylinositol 3-kinase and is
independent of mitogen-activated protein kinase. J Biol Chem 272: 31163-31171
97

Elmlinger MW, Sanatani MS, Bell M, Daimecker GE, Ranke MB. (1998) Elevated
insulin-like growth factor binding protein 2 and IGFBP-4 expression of leukemic
T-cells is affected by autocrine/paracrine IGF-II action but not by IGF-I receptor
expression. Eur J Endocrinol 138: 337-343

Ebrenborg E, Vilbemsdotter S, Bajalica S, Larsson C, Stem I, Kocb J, Brondum-Nielsen
K, Lutbman H. 1991 Stmcture and localization of the human insulin-like growth
factor binding protein-2 gene. Biocbem Biopbys Res Commim. 176: 1250-1255

El-Mowafy AM,Alkbalaf M.(2003)Resveratrol activates adenylyl-cyclase in human
breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism.
Carcinogenesis 24(5): 869-873

Farrelly N, Lee YJ, Oliver J, Dive C, Streuli CH. 1999 Extracellular matrix regulates
apoptosis in mammary epithelium through a control on insulin signaling. J Cell
Biol. 14: 1337-1348

Frasca F,Pandini G, Scalia P.(1999)Insulin receptor isoform A,a newly recognized,
high affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol
Cell Biol 19: 3278-3288

Fulda S, Debatin KM.(2004) Sensitization for anticancer dmg-induced apoptosis by the
chemopreventive agent resveratrol. Oncogene. 23(40): 6702-6711
Furlanetto RW,Harwell SE, Frick KK. 1994 Insulin-like growth factor-I induces cyclinD1 expression in MG63 human osteosarcoma cell in vitro. Mol Endocrinol 8:
510-517

Garcia D., Derocq D., Pujol P., Rochefort H.(1990) Overexpression of transfected
cathepsin D in transformed cells increases their malignant phenotype and
metastatic potency. Oncogene 5:1809-1814

Gehm BD,MeAndrews JM, Chien PY,Jameson JL 1997 Resveratrol, a polyphenolic
compound found in grapes and wine, is an agonist for the estrogen receptor. Proc
Natl Acad Sci 94:4138-43

Gehm B.D., Levenson A.S., Liu A., Lee E.J., Amudsen B.M., Cushman M., Jordan V.C.,

Jameson J.L.(2004)Estrogenic effects ofresveratrol in breast cancer cells
expressing mutant and wild-type estrogen receptors: Role of AF-1 and AF-2. J.
Steroid Biocbem. Mol. Biol. 88(3): 223-234

Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C. 1993 Parental
genomic imprinting ofthe human IGF-2 gene. Nat Genet 4: 98-101
Gilmore AP, Valentijn AJ, Wang P, et al. 2002 Aetivation of BAD by therapeutic
inhibition of epidermal growth factor receptor and transactivation by insulin-like
growth factor receptor. J Biol Chem. 277: 27643-27650
98

Glondu M., Coopman P., Laurent-Matha V., Garcia M., Rochefort H., Liaudet-Coopman
E.(2001) A mutated cathepsin D devoid of its catalytic activity stimulates the
growth of cancer cells. Oncogene 20(47): 6920-9

Goldberg DM, Garovic-Kocic V, Diamandis EP, Pace-Asciak ER. 1996 Wine: does the
color count? Clin Chim Acta. 246: 183-193

Gowan LK,Hampton B,Hill DJ, Schlueter RJ,Perdue JF 1987 Purification and
characterization of a unique high molecular weight form ofinsulin-like growth
factor II. Endocrinology 121: 2050-55

Hasegawa T, Cohen P, Rosenfeld RG. 1995 Characterization of the insulin -like growth
factor axis in TM 3 Leydig cells. Growth Regul 5: 151-159

Haselbacher GK,Irminger JC,Zapf J, Ziegler WH,Humbel RE 1987 Insulin-like growth
factor II in human adrenal pheochromocytoma and Wilms' tumors:expression at
mRNA and protein levels. Proc Natl Acad Sci 84(4): 1104-6

Hoeflich A,Yang Y,Rascher W,Blum WF,Huber S, Koepf G,Kolb HJ, Kiess W.
(1996)Coordinate expression of insulin-like growth factor II(IGF-II) and IGFII/mannose-6-phosphate receptor mRNA and stable expression ofIGF-I receptor
mRNA during differentiation of human colon carcinoma cells(Caco-2). Eur J
Endocrinol 135(1): 49-59

Hongo A,D'Ambrosio C, Miura M,Morrione A,Baserga R.(1996) mutational analysis
ofthe mitogenic and transforming activities ofthe insulin-like growth factor I
receptor. Oncogene 12: 1231-1238

Hoppener JW, Mosselman S, Hekoll PJ 1988 Expression ofinsulin-like growth factor I
and II genes in human smooth muscle tumors. EMBO J 7: 1379-85
Hsieh TC,Burfeind P,Laud K,Backer JM,Traganos F, Darzynkiewicz Z, Wu JM 1999
Cell cycle effects and control of gene expression by resveratrol in human breast
carcinoma cell lines with different metastatic potentials. Int J Oncol 15: 245-52

Hu JF, Oruganti H, Yu TH, Hoffman AR. 1998 The role of histone acetylation ih the
allelic expression of the imprinted human insulin-like growth II gene. Biochem
Biophys Res Commun 251: 403-408

Huang C, Ma WY,Goranson A,Dong Z. 1999 Resveratrol suppresses cell transformation
and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20: 237242

Hwa V, Oh Y, Rosenfeld RG. 1999 The insulin-like growth factor binding protein
superfamily. Endocr Rev 20:761-787

Iwase H, Itoh Y, Kuzushima T, Yamashita H, Iwata H. 1997 Simultaneous quantitative

analyses of c-erbB-2 protein, epidermal growth factor receptor, Cathepsin D, and
hormone receptors in breast cancer. Cancer Detect Prev 21: 29-35
99

Jang M, Cai L, Udeani GO. 1997 Cancer chemopreventive activity of resveratrol, a
natural product derived from grapes. Science 275: 218-220

Jang M,Cai L,Udeani GO,Showing KV,Thomas CF,Beecher CW,Pong HH,
Famsworth NR,Kinghom AD,Mehta RG,Moon RC,Pezzuto JM.(1997)Cancer
chemopreventive activity ofresveratrol, a natural product derived from grapes.
Science 275(5297): 218-220

Jansen M, Van Schaik FM, Richer AT, Bullock B, Woods DE, Gabbay KH. 1983
Sequence ofcDNA encoding human insulin-like growth factor I precursor. Nature
306: 609-611

Jarrad DF, Bussemakers MJ, Bova GS, Issacs WB. 1995 Regional loss of imprinting of
the insulin-like growth factor II gene occurs in human prostate tissues. Clin
Cancer Res. 1:1471-1478

Jeandet P, Bessis R, Gautheron B 1991 The production of resveratrol by grape berries in
different developmental stages. Am J Enol Vitic. 42: 41-46
Jones JI, Clemmons DR. 1995 Insulin-like growth factors and their binding proteins:
biological actions. Endoc Rev 16: 3-34

Karey KP,Sirbasku DA.(1988)Differential responsiveness of human breast cancer cell
lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res
48(14): 4083-4092

Katz EEL, Rosenfeld RG, Cohen P. 1995 Clinical significance of insulin-like growth
factor binding proteins. Endocrinology 5: 36-43
Katz J, Weiss H, Goldman B, Kanety H, Stannard B, LeRoith D, Shemer J. 1995
Cytokines and growth factors modulate cell growth and insulin-like growth factor

binding protein secretion by the human salivary cell line (HSG). J Cell Physiol.
165: 223-227

Kellerer M,Lammers R,Ermel B.(1992)Distinct alpha-subunit structures of human
insulin receptor A and B variants determine differences in tjn-osine kinase
activities. Biochemistry 31: 4588-4596

Khandwala H,McCutcheon I, Flyvbjerg A,Friend K(2000)The effects of insulin-like
growth factors on tumorigenesis and neoplastic growth. 21(3): 215-244
Kiess W,Thomas Cl, Greenstein LA,Lee L, Sklar MM,Rechler MM,Sahagian GG,

Nissley SP.(1989)Insulin-like growth factor-II(IGF-II)inhibits both the cellular
uptake of P-galactosidase and the binding of p-galactosidase to purified M6P/IGF-II recptor. J Biol Chem 264: 4710-4714

100

Kim EJ, Holthuizen PE,Kim J, Park JH.(2005) Overexpression of mature insulin-like
growth factor II leads to growth arrest in Caco-2 human colon cancer cells.
Growth Hormone and IGF Research. 15: 64-71

Kitadai Y,Yamazaki H,Yasui W,Kyo E,Yokozaki H,Kajiyama G,Johnson AC,Pastan
I, Tahara E 1993 GC factor represses transcription ofseveral growth
factor/receptor genes and causes growth inhibition of human gastric carcinoma
cell lines. Cell Growth Differ 4(4): 291-6

Klinge C.(2001)Estrogen receptor interaction with estrogen response elements. Nucleic
Acid Research 29: 2905-2919

Klinge CM,Blankenship KA,Risinger BCE, Bhatnagar S, Noisin EL, Sumanasekera WK,
Zhao L, Brey DM. 2005 Resveratrol and estradiol rapidly activate MAPK

signaling through estrogen receptors a and P in endothelial cells. J Biol Chem
280(9): 7460-8

Kommann M,Arber N,Korc M. 1998 Inhibition of basal and mitogen-stimulated
pancreatic cell growth by cyclin D1 antisense is associated with loss of
tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest
101:344-352

Komfeld S.(1992) Structure and function ofthe mannose-6-phosphate/insulin-like
growth factors receptors. Ann Rev Biochem 61: 307-330

Krajcik RA,Borofsky ND,Massardo S, Orentreich N.2002 Insulin-like growth factor I
(IGF-I),IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers
Prev(I2): 1566-73

Krajewski S, Krajewska M., Tumer B,Pratt C,Howard B,Zapata J, Frenkel V,
Robertson S, Lonov Y,Yamamoto H,Perucho M,Takayama S,Reed J(1999)
Prognostic significance of apoptosis regulators in breast cancer. EndocrineRelated Cancer 6: 29-40

Kuiper GG,Lemmen JG, Carlsson B, Gorton J, Safe SH, Van Der Saag P, Van Der Burg
B, Gustafsson J-A. 1998 Interaction of estrogenic chemicals and phytoestrogens
with estrogen receptor beta. Endocrinology 139: 4252-4263

Kulik G, Weber MJ.(1998) Akt-dependent and -independent survival signaling pathways
utilized by insulin-like growth factor I. Mol Cell Biol II: 6711-6718
Kuwajerwala N., Cifuentes E., Gautam S., Menon M., Barrack E., Reddy G. 2002
Resveratrol induces prostate cancer cell entry into S phase and inhibits DNA
synthesis. Cancer Research (62): 2488-2492

LeRoith D,Werner H,Beitner-Johnson D,Roberts CT Jr.(1995) Molecular and cellular
aspects ofthe insulin-like growth factor I receptor. Endocr Rev 16: 143-163

lOI

LeRoith D,Roberts CT Jr.(2003)The insulin-like growth factor system and cancer.
Cancer Letters 195: 127-137

Leto G., Tumminello P.M., Creseimanno M., Flandina C., Gebbia N.(2004)Cathepsin D
expression levels in non-gynecological solid tumors: clinical and therapeutic
implications. Clin. Exp. Metastasis 21 (2): 91-106
Levenson AS, Jordan VC. 2000 Selective estrogen receptor modulation: molecular
pharmacology for the millennium. Eur J Cancer. 35: 1628-1639
Levenson AS, Gehm BD,Pearce ST, Horiguchi J, Simons LA, Ward JE, Jameson JL,
Jordan VC 2003 Resveratrol acts as an estrogen receptor(ER)agonist in breast
cancer cells stably transfected with ERa.Int J Cancer 104: 586-96

Liaudet E., Garcia M.,Rochefort H.(19940 Cathepsin D maturation and its stimulatory
effect on metastasis are prevented by addition ofKDEL retention signal.
Oncogene 9:1145-1154

Louafi F, Stewart CE,Perks CM,Thomas MG,Holly JM.(2003)Role ofthe IGF-II

receptor in mediating acute, non-genomic effects ofretinoids and IGF-II on
keratinocyte cell death. Exp Dermatol 12(4): 426-434

Louvi A, Aeeili D,Efstratiadis A.(1997) Growth-promoting interaction ofIGF-II with
the insulin receptor during mouse embryonic development. Dev Biol 189: 33-48
Lu R, Serrero G 1999 Resveratrol, a natural product derived from grape, exhibits
antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell
Phys 179: 297-304

Maxwell P, van den Berg HW. 1999 Changes in the secretion of IGF binding proteins-2
and -4 associated with the development of tamoxifen resistance and estrogen
independence in human breast cancer cell lines. Cancer Letters 139: 121-127
Mathieu M,Rochefort H,Barenton B,Prebois C, Vignon F.(1990)Interactions of
cathepsin D and IGF-II on the mannose-6-phosphate/IGF-II receptor in human
breast cancer cells and possible consequences on mitogenie activitiy ofIGF-II.
Mol Endocrinology 4: 1327-1335

McKusker RH, Clemmons DR. 1992 The insulin-like growth factor binding proteins:
Structure and biological functions. The insulin-like growth factors. Structure and
biological functions(EdPN Schofield) 110-149

Mgbonyebi OP,Russo J, Russo IH 1998 Antiproliferative effect of synthetic resveratrol
on human breast epithelial cells. Int J Oncol 12: 865-69

Mineo R,Fiehera E, Liang S-J, Fujita-Yamaguehi Y.(2000)Promoter usage for insulin
like growth factor-II in cancerous and benign human breast, prostate, and bladder

tissues, and confirmation of a lO^'' exon. Biochem and Biophys Res Commun 268:
886-892
102

Minshall C, Arkins S, Straza J, Conners J, Dantzer R, Freund GG, et al. 1997 IL-4 and
insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival
ofIL-3-deprived myeloid progenitors. J Immunol 159: 1225-1232

Miura M,Li S, Baserga R.(1995)Effect of a mutation at tyrosine 950 of the insulin-like
growth factor I receptor on the growth and transformation of cells. Cancer
Research 55: 663-667

Miyakoshi N,Richman C,Kasukawa Y,Linkart TA,Baylink DJ, Mohan S.(2001)
evidence that IGF-binding protein 5 functions as a growth factor. J Clin Invest
107: 73-81

Mizutani K, Ikeda K, Kawai Y, yamori Y. 2000 resveratrol attenuates ovariectomyinduced hypertension and bone loss in stroke-prone spontaneously hypertensive
rats. JNutr Sci Vitaminol(Tokyo). 46: 78-83

Mohan S, Bautista CM, Wergedal J, Baylink DJ.(1989) Isolation of an inhibitory IGFbinding protein from bone cell-conditioned medium: A potential local regulator of
IGF action. Proc Natl Acad Sci USA 86: 8338-8342

Mohan S, Baylink DJ.(1995) Development of a simple valid method for the complete
removal of IGF-binding proteins from IGFs in human serum and other biological
fluids: comparison with acid-ethanol treatment and C18 Sep-Pak separation. J
Clin Endocrinol Metab 80: 637-647

Morgan DO,Edman JC, Standring DN,Fried VA,Smith MC,Roth RA,Rutter WJ.
(1987)Insulin-like growth factor II receptor as a multifunctional binding protein.
Nature 329: 301-307

Montcourrier P, Silver I.A., Famoud R., Bird I., Rochefort H.(1997)Breast cancer cells
have a high capacity to acidify extracellular milieu by a dual mechanism. Clin.
Exp. Metast.l5: 382-3892
Muller HL, Oh Y, Lehmbecher T, Blum WF, Rosenfeld RG. 1994 Insulin-like growth

factor binding protein-2 concentrations in cerebrospinal fluid and serum of
children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab.
79: 428-434

Murphy LJ, Molnar P,Lu X,Huang H.(1995)Expression of human insulin-like growth
factor binding protein 3 in transgenic mice. J Mol Endocrinol 124: 707-714
Nakagawa Y,Yamaguchi S, Hasegawa M,Nemoto T,Inoue M,Suzuki K,Hirokawa K,
Kitagawa M.(2004)Differential expression of survivin in bone marrow cells
from patients with acute lymphocytic leukemia and chronic lymphocytic
leukemia. Leukemia Research 28(5): 487-494

103

Nakagawa H,Kiyozuka Y,Uemura Y, Senzaki H,Shikata N,Hioki K,Tsubura A 2001
Resveratrol inhibits human breast cancer cell growth and may mitigate the effect
oflinoleic acid, a potent breast cancer stimulator. J Cancer Res Clin Oncol 127:
258-64

Nam TJ, Busby WH,Rees C,Clemmons DR.(2000)Thrombospondin and osteopontin
bind to insulin-like growth factor binding protein 5 leading to an alteration in
IGF-I stimulated cell growth. Endocrinology 141: 1100-1106

Nickerson T, Pollak M,Huynh H.(1998) Castration-induced apoptosis in the rat ventral
prostate is associated with increased expression of genes encoding insulin-like
growth factor binding proteins 2, 3,4, and 5. Endocrinology 139: 807-810
Noble A,Towne C, Chopin L,Leavesley D,Upton Z.(2003)Insulin-like growth factor II
bound to vitronectin enhances MCF-7 breast cancer cell migration. Endocrinology
144(6): 2417-2424

Gates AJ, Schumaker LM,Jenkins SB,Pearce AA,DaCosta SA, Arun B.(1998)The
mannose-6-phosphate/insulin-like growth factor 2 receptor(M6P/IGF2R), a
putative breast tumor suppressor gene. Breast Cancer Res Treat 47: 269-281
O'Connor R, Kauffmann-Zeh A,Liu Y,Lehar S, Evan GI, Baserga R,Blattler WA.

(1997)Identifications of domains ofthe insulin-like growth factor I receptor that
are required from protection from apoptosis. Molecular and cellular Biology 17:
427-435

Oda H, Shimizu S, Minami K, Kaneko K, Ishikawa T. 1997 Loss of imprinting of the
IGF2 gene in a Wilms' tumor in an adult. J Natl Cancer Inst. 89: 1813-1814

O'Dell SD,Day 1.(1998) Molecules in focus insulin-like growth factor 11. The
International Journal of Biochemistry and Cell Biology 30: 767-771
Ogawa O,Eccles MR,Szeto J, McNoe LA,Yun K,Maw MA,Smith PJ, Reeve AE.
(1993)Relaxation ofinsulin-like growth factor II gene imprinting implicated in
Wilms'tumour. Nature 362: 749-751

Ogihara T,Isobe T,Ichimura T, Taoka M,Funaki M,Sakoda H,Onishi Y,Inukai K,
Anai M,Fukushima Y,Kikuchi M,Yazaki Y,Oka Y, Asano T.(1997) 14-3-3
protein binds to insulin receptor substrate-1, one ofthe binding sites of which is in
the phosphotyrosine binding domain. J Biol Chem 272(40): 25267-25274
Oh Y. (1998) IGF-independent regulation of breast cancer growth by IGF binding
proteins. Breast Cancer Res Treat 47: 283-293

Osbome CK,Coronado EB,Kitten LJ, Arteaga CI, Fuqua SA,Ramasharma K, Marshall
M,Li CH.(1989)IGF-II: a potential autocrine/paracrine factor for human breast
cancer acting via the IGF-I receptor. Mol Endocrinol 3: 1701-1709
104

Oshima A,Nolan CM,Kyle JW,Grubb JH, Sly WS.(1988)The human cationindependent mannose-6-phosphate receptor. Cloning and sequence ofthe fulllength cDNA and expression offunctional receptor in cos cells. J Biol Chem 263:
2553-2562

Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM. 1996 Wine and
grape juices as modulators of platelet aggregation in healthy human subjects. Clin
ChimActa. 246: 163-182

Park J-W, Choi Y-J, Suh S-I, Back W-K,Suh M-H,Jin I-N, Min Ds, Woo J-H, Chang JS,Passaniti A,LeeYH,Kwon TK. (2001)Bcl-2 overexpression attenuates

resveratrol-induced apoptosis in U957 cells by inhibition of Caspase 3 activity.
Carcinogenesis 22(10): 1633-1639

Parrizas M, LeRoith D. 1997 Insulin-like growth factor I inhibition of apoptosis is
associated with increased expression of the bcl-xL gene product. Endocrinology
138: 1355-1358

Pell JM, Saunders JC, Gilmour RS. 1993 Differential regulation oftranscription initiation
from insulin-like growth factor I (IGF-I) leader exons and of tissue IGF-I
expression in response to changed growth hormone and nutritional status in sheep.
Endocrinology 132: 1797-1807

Perdue JF, LeBon TR,Kato J, Hampton B,Fujita-Yamaguchi Y(1991)Binding
specificities and transducing function ofthe different molecular weight forms of
IGF-II on IGF-IR. Endocrinology 129(6): 3101-3108

Perkel VS, Mohan S, Baylink DJ, Linkart TA.(1990) An inhibitory insulin-like growth
factor binding protein(IN-IGFBP)from human prostatic cell conditioned medium
reveal N-terminal sequence identity with bone derived IN-IGFBP. J Clin
Endocrinol Metab 71: 533-535

Peruzzi F, Frisco M,Dews M,Salomoni P, Grassilli E,Romano G, Calabretta B,Baserga
R.(1999) Multiple signaling pathways ofthe insulin-like growth factor 1 receptor
in protection from apoptosis. Mol Cell Biol 10: 7203-7215

Pollak M,Schemhammer E, Hankinson S (20,04)Insulin-like growth factors and
neoplasia. Nature Reviews 4: 505-518
Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F,

Alvarez-Barrientos A,Salguero PM.(2005) Resveratrol-induced apoptosis in
MCF-7 human breast cancer cells involves a caspase-independent mechanism
with downregulation of Bcl-2 and NF-kappaB. Int J Cancer. 115(1): 74-84

Pozo-Guisado E., Lorenzo-Benayas M. J., Femandez-Salguero P. M.2004 Resveratrol
modulates the phosphoinositide 3-kinase pathway through an estrogen receptor adependent mechanism: relevance in cell proliferation. Int. J. Cancer 109: 167-173
105

Pugazhenthi S, Miller E, Sable C,Young P,Heidenreich KA,Boxer LM,Reusch J.
(1999)IGF-I induces Bcl-2 promoter through the transcription factor campresponse element-binding protein. J Biol Chem 274(39): 27529-27535

Quinn KA,Treston AM,Unsworth EJ.(1996)Insulin-like growth factor expression in
human cancer cell lines. J Biol Chem. 271: 11477-11483

Ragione FD, Cucciolla B, Borriello A. 1998 Resveratrol arrests the cell division cycle at
S/G2 phase transition. Biochem Biophys Res Commun 250: 53-58

Rasmussen AA,CullenKJ.(1998)Paracrine/autocrine regulation of breast cancer by the
insulin-like growth factors. Breast Cancer Res Treat 47(3): 219-233
Renehan AG,Jones J, Potten CS, Shalet SM,O'Dwyer ST.(2000)Elevated serum

insulin-like growth factor-II and binding protein-2 in patients with colorectal
cancer. Br J Cancer 83: 1344-1350

Reeve AE,Eccles MR,Wilkins RJ, Bell GI, Millow LJ 1985 Expression of insulin-like
growth factor II transcripts in Wilms' tumor. Nature 317: 258-60

Rochefort H. 1996 The prognostic value of cathepsin D in breast cancer. A long road to
the clinic. Eur J Cancer 32A: 7-8

Rochefort H,Capony F, Garcia M,Cavailles V,Freiss G,Chambon M,Morisset M,

Vignon F.(1987)Estrogen-induced lysosomal proteases secreted by breast cancer
cells: a role in carcinogenesis? J Cell Biochem 35(1): 17-25

Rochefort H., Cavailles V., Augereau P., Capony F., Maudelonde T., Touitou I., Garcia
M.(1989)Overexpression and hormonal regulation of pro-cathepsin D in
mammary and endometrial cancer. J. Steroid Biochem. 34:177-182

Rochefort H., Garcia M., Glondu M., Laurent V., Liaudet E., Rey J.M., Roger P.(2000)
Cathepsin D in breast cancer: Mechanisms and clinical applications, a
1999overview. Clinica Quimica Acta 291:157-170

Rosenfeld RG, Lamson G, Pham H, Oh Y, Conover C, DeLeon DD. 1990 Insulin-like
growth factor binding proteins Recent Prog Horm Res. 46: 99-159

Rubin R,Baserga R.(1995)Insulin-like growth factor I receptor. Its role in cell
proliferation, apoptosis and tumorigenicity. Laboratory Investigation 73: 311-331
Ruibal A., Arias, J.I.(2004) Axillary lymph node involvement in hormone-independent
breast carcinomas. Med. Clin. 123 (2): 50-52

Ruoslathi E, Pierschlaber MD. 1987 New perspectives in cell adhesion: RGD and
integrins. Science 238: 491-497

106

Sachdev D,Yee D.(2001)The IGF system and breast cancer. Endocrine-Related Cancer
8: 197-209

Sara VR,Hall K. 1990 Insulin-like growth factors and their binding proteins. Physiol Rev
70:591-614

Scharla SH, Strong DD, Mohan S, Baylink DJ, Linkart TA. (1991) 1,25-

Dihydrox}witamin D3 differentially regulates the production of insulin-like
growth factor I (IGF-I) and IGF-binding protein 4 in mouse osteoblasts.
Endocrinology 129: 3139-3146

Schneider Y, Vincent F, Duranton B,Badolo L, Gosse F, Bergmann C, Seiler N,Raul F
2000 Anti-proliferative effect ofresveratrol, a natural component of grape and
wine, on human colonic cancer. Cancer Lett 158: 85-91

Sciacca L, Costantino A,Pandini G, Mineo R,Frasca F, Scalia P, Sbraccia P, Goldfine
ID, Vigneri R,Belfiore A 1999 Insulin receptor activation by IGF-II in breast
cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18:247179

Sciacca L, Mineo R,Pandini G, Murabito A, Vigneri R,Belfiore A 2002 In IGF-I

receptor deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion
and protection from apoptosis via the insulin receptor isoform A. Oncogene
21:8240-50

Scott CD,Firth SM 2004 The role ofthe M6P/IGF-II receptor in cancer: Tumor

suppression or garbage disposal? Horm Metab Res 36: 261-71

Seino S, Bell GI.(1989) Alternative splicing of human insulin receptor messenger RNA.
Biochem Biophys Res Commun 159: 312-316

Sepp-Lorenzino L.(1998) Structure and function ofthe insulin-like growth factor I
receptor. Breast Cancer Res Treat 47: 235-253

Shiekh MS,Shao ZM,Hussain A,Clemmons DR,Chen JC, Roberts CT Jr, LeRoith D,
Fontana JA.(1993)Regulation ofinsulin-like growth factor binding protein 1, 2,
3,4, 5 and 6: synthesis, secretion and gene expression in estrogen receptor
negative human breast carcinoma cells. J Cell Physiol 155: 556-567

Shimaki S, Ling N. 1991 Identification and molecular characterization of insulin-like
growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, and -6). Prog Growth
Factor Res 3: 243-266

Shin S, Sung B-J, Cho Y-S,Kim H-J, Ha N-C,Hwang J-I, Chung C-W,Jung Y-K, Oh BH.(2001) An anti-apoptotic protein human survivin is a direct inhibitor of
Caspase-3 and -7. Biochemistry 40: 1117-1123

107

Singer C,Rasmussen A, Smith HS,Lippman ME,L^ch HT,Cullen KJ.(1995)
Malignant breast epithelium selects for insulin-like growth factor-II expression in
breast stroma: evidence for paracrine function. Cancer Research 55: 2448-2454

Singhal H., Guo L., Bradlow H.L., Mittelman A., Tiwari R.K.(1999)Endocrine
characteristics of human breast epithelial cells, MCF-IOF. Horm. Res. 52: 171177

Spom MB,Suh N.(2000)Chemoprevention of cancer. Carcinogenesis 21(3): 525-530
Soleas GJ, Diamandis EP, Goldberg DM. 1997 Wine as a biological fluid: history,
production, and role in disease prevention. J Clin Lab Anal 11: 2287-313
Stewart CE,Rotwein P.(1996) Growth, differentiation, and survival: multiple
physiological functions for insulin-like growth factors. Physiol Rev 76: 10051026

Stewart A, Westley B, May F.(1992) Modulation ofthe proliferative response of breast
cancer cells to growth factors by estrogens. Brit J Cancer 66: 640-648
Sthal S., Chun T-Y, Gray W. 1998 Phytoestrogens act as estrogen agonists in an
estrogen-responsive pituitary cell line. Toxicology and Applied Pharm (152): 4148

Storrie B,Desjardin M.(1996)the biogenesis of lysosomes: is it a kiss and run,
continuous fusion and fission process? Bioassays 18: 895-903Toretsky JA,
Helman LJ 1996 Involvement ofIGF-II in human cancer. J Endocrinol 149(4):
367-72

Sussenbach JS, Rodenburg RJ, Scheper W,Holthuizen P. 1993 Transcriptional and posttranscriptional regulation ofthe human IGF-II gene expression. Adv Exp Med
Biol. 343: 63-71

Takahashi T., Tang J.(1981)Cathepsin D from porcine and bovine spleen. Methods
Enzymol. 80: 565-581

Tessitore L, Davit A, Sarotto, Cademi G. 2000 Resveratrol depresses the growth of

colorectal aberrant crypt foci by affecting bax and p21^'^ expression.
Carcinogenesis 21: 1619-1622

Tobin G, Yee D, Brunner N, Rotwein P. 1990 A novel insulin-like growth factor I
mRNA is expressed in normal and tumor cells. Mol Endocrinol. 4: 1914-1920
Tsujimoto Y (1998)Role of Bcl-2 family proteins in apoptosis: apoptosomes or
mitochondria? Genes to Cells 3: 697-707

108

Uhles S, Moede T,Leibiger B,Berggren PO,Leibiger IB.(2003)Isoform specific insulin
receptor signaling involves different plasma membrane domains. J Cell Biol 163:
1327-1337

Umayahara Y,Kawamori R, Watada H,Imano E,Iwama N, Morishima T,Yamasaki Y,
Kajimoto Y,Kamada T.(1994)Estrogen regulation of the insulin-like growth
factor 1 gene transcription involves an AP-1 enhancer. J Biol Chem 269: 1643316442

Valenzano KJ, Heath-Monnig E, Tollefsen SE, Lake M,Lobel P 1997 Biophisieal and
biological properties of naturally occurring high molecular weight lGF-11 variants.
J Biol Chem 272(8): 4804-13

Vetvika V., Benes P., Fusek M. (2002)Procathepsin D in breast cancer: what do we
know? Effects ofribozymes and others inhibitors. Cancer Gene Therapy 9: 854863

Vignon F, Roehefort H.(1992)Interactions of pro-cathepsin D and lGF-11 on the
mannose-6-phosphate/lGF-ll receptor. Breast Cancer Res Treat 22: 47-57

Vilmos P, Gaudenz K, Hegedus Z, Marsh JL. 2001 The twisted gastrulation family of
proteins, together with the IGFBP and CCN families, comprises the TIC
superfamily of eysteine rich secreted factors. Mol Pathol 54: 317-323

Vogt B, Carrascosa JM,Ermel B,Ullrich A,Haring HU.(1991)The isotypes ofthe
human insulin receptor(HIR-A and HIR-B)follow different intemalization
kinetics. Biochem Biophys Res Commun 177: 1013-1018

Volpert O, Jackson D, Bouck N and Linzer Dl. 1996 The insulin-like growth factor
11/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis.
Endocrinology 137: 3871-3876

Vu TH, Hoffman AR. 1994 Promoter-specific imprinting of the human insulin-like
growth factor 11 gene. Nature 371: 714-717
Wan X,Helman LJ.(2002)Effect ofinsulin-like growth factor 11 on protecting myoblast
cells against cisplatin-induced apoptosis through p70 S6 kinase pathway.
Neoplasia 4(5): 400-408

Wang L, Ma W, Markovich R, Lee WL, Wang PH. 1998 Insulin-like growth factor 1
modulates induction of apoptotic signaling in H9C2 cardiac muscle cells.
Endocrinology 139(3): 1354-60

Ward A., Bates P., Fisher R. Richardson L., Graham C.F. 1994 Disproportionate growth
in mice with lGF-11 transgenes. PNAS 91: 10365-10369
Werner H,Adamo M,Roberts CT Jr, LeRoith D 1994 Molecular and cellular aspects of
insulin-like growth factor action. Vitam Horm 48: 1-58
109

Westley BR,May FE 1996 Cathepsin D and breast cancer. Eur. J Cancer 32A(1): 15-24
Williams KP,Smith JA.(1993)Isolation of membrane-associated cathepsin D like
enzyme from the model antigen presenting cell, A20,and its ability to generate
antigenic fragments from protein antigen in a cell free system. Arch Bioehem
Biophys 305: 298-306

Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ. 2001 Mechanism of
eardioproteetion by resveratrol, a phenolic antioxidant present in red wine. Int J
Mol Med. 8: 3-17

Wutz A, Barlow DP. 1998 Imprinting of the mouse IgfZr gene depends on an intronic
CpG island. Mol Cell Endocrinol. 140: 9-14

Xing W., Archer T.(1998)Upstream stimulatory factors mediate estrogen receptor
activation ofthe cathepsin D promoter. Molecular Endocrinology 1310-1321

Yamaguchi Y,Flier JS, Yokota A,Beneeke H,Backer JM,Moller DE.(1991)Functional
properties oftwo naturally occurring isoforms ofthe human insulin receptor in
Chinese hamster ovary cells. Endocrinology 129: 2058-2066

Yamamoto Y, Wada O, Suzawa M,Yogiashi Y,Yano T, Kato S, Yanagisawa J. 2001
The Tamoxifen-responsive estrogen receptor a mutant D351Y shows reduced
tamoxifen-dependent interaction with eorepressor complexes. J Biol Chem
276:42684-42691

Yang Q,Sakurai T, Jing X,Utsunomiya H,Shan L, Nakamura Y,Nakamura M,Oura S,
Suzuma T, Yoshimura G,Umemura T,Kokawa Y,Kakudo K(1999)Expression
of Bcl-2 but not Bax, correlates with estrogen receptor status and tumor

proliferation in invasive breast carcinoma. Pathology International 49:775-780

Yang CQ,Zhan X,Hu X,Kondepudi A,Perdue JF(1996)The expression and
characterization of human recombinant proIGF-II and a mutant that is defective in
the 0-glycosylation of its E-domain. Endocrinology 137(7): 2766-2773
Yee D, Sachdev D (2001)The IGF system and breast cancer. Endocrine-Related Cancer
8: 197-209

Yee D,Lee AV 2000 Crosstalk between the insulin-like growth factors and estrogens in
breast cancer. J of mammary Gland Biol and Neoplasia 5:107
Yun K,Jinno Y,Sohda T, Niikawa N,Ikeda T. 1998 Promoter-specific insulin-like

growth factor 2 gene imprinting in human fetal liver and hepatoblastoma. J pathol
185:91-98

Zapf J. 1995 Physiological role ofthe insulin-like growth factor binding proteins. Eur J
Endocrinol 132: 645-654Zhan S, Shapiro D,Zhan S,Zhang L, Hirschfeld S,
110

UNIVERSITY LIBRARY
LOMA LINDA, CALIFORNIA
Elassal J, Helman LJ.(1995)Concordant loss ofimprinting ofthe human insulin
like growth factor II gene promoters in cancerJ Biol Chem 270(47):27983-27986

Zhang J, Whitehead RE Jr., Underwood EE. 1997 Effdct offasting on insulin-like growth
factor (IGF)-IA and IGF-IB mRNAs and prehormones in rat liver. Endocrinology
138:3112-3118

Zhang S, Cao HJ, Davis FB,Tang HY,Davis PJ, Lin HY.(2004) Oestrogen inhibits
resveratrol-induced post-translational modification of p53 and apoptosis in breast
cancer cells. Br J Cancer. 91(1): 178-85

Zhang L,Kashanchi F,Zhan Q,Brady JN,Fomace AJ, Seth P, Helman LJ 1996
Regulation ofinsulin-like growth factor IIP3 promoter by p53: A potential
mechanism for tumorigenesis. Cancer Res 56: 1367-73

111

